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ABSTRACT 
Prostate Cancer is the leading cause of cancer-related death in males in the Western 
world. It is a common biological disease originating from the reproductive system of 
the male namely, the prostate gland, usually in older patients (over the age of 50) and 
with a family history of this disease. The disease shows clinical aggressiveness due to 
genetic alterations of gene expression in prostate epithelial cells. Prostate cancer is 
currently diagnosed by biopsy and prostate cancer screening via the Prostate-Specific 
Antigen (PSA) blood test. Early detection is critical and although PSA was discovered 
to aid in the diagnoses of this cancer at its early stages, it has a disadvantage due to its 
low specificity thus causing unnecessary biopsies of healthy individuals and over-
treatment of patients. Although various studies and efforts have been made to identify 
the ideal biomarker for prostate cancer and many even being applied to clinical use, it 
is still challenging and has not replaced the best-known biomarker PSA. PSA test has 
minimal invasive characteristics, at relatively low cost together with high sensitivity 
but low specificity. Biomarker discovery is a challenging process and a good biomarker 
has to be sensitive, specific and its test highly standardized and reproducible as well as 
identify risk for or diagnose a disease, assess disease severity or progression, predict 
prognosis or guide treatment. Computational biology plays a significant role in the 
discovery of new biomarkers, the analyses of disease states and the validation of 
potential biomarkers. Bioinformatic approaches are effective for the detection of 
potential micro ribonucleic acid (miRNA) in cancer. Altered miRNA expression may 
serve as a biomarker for cancer diagnosis and treatment.  Small non-protein coding RNA, 
miRNA are small regulatory RNA molecules that modulate the expression of their target 
genes. miRNAs influence numerous cancer-relevant processes such as proliferation, cell 
cycle control, apoptosis, differentiation, migration and metabolism. Discovery and 
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existence of extracellular miRNAs that circulate in the blood of cancer patients has 
raised the possibility that miRNAs may serve as novel diagnostic markers.  Since a single 
miRNA is said to be able to target several mRNAs, aberrant miRNA expression is 
capable of disrupting the expression of several mRNAs and proteins. Biomarker 
discovery for prostate cancer of mRNA and miRNA expression are strongly needed to 
enable more accurate detection of prostate cancer, improve prediction of tumour 
aggressiveness and facilitate diagnosis. 
The aim of this project was to focus on functional analyses of genes and their protein 
products regulated by previously identified miRNA in prostate cancer using 
bioinformatics as a tool. Most proteins function in collaboration with other proteins and 
therefore this study further aims to identify these protein-protein interactions and the 
biological relevance of these interactions as it relates to Prostate cancer. Various 
computational databases were used such as STRING, DAVID and GeneHub-GEPIS 
for functional analyses of these miRNA regulated genes. The main focus was on the 21 
genes regulated by several miRNAs identified in a previous study. Results from this 
study identified six genes; ERP44, GP1BA, IFNG, SEPT2, TNFRSF13C and 
TNFSF4, as possible diagnostic biomarkers for prostate cancer. These results are 
promising, since the targeted biomarkers would be easily detectable in bodily fluids 
with the Gene Ontology (GO) analysis of these gene products showing enrichment for 
cell surface expression.   The six genes identified in silico were associated to 
transcription factors (TFs) to confirm regulatory control of these TFs in cancer 
promoting processes and more specifically prostate cancer.  The CREB, E2F, Nkx3-1 
and p53 TFs were discovered to be linked to the genes IFNG, GP1BA, SEPT2 and 
TNFRSF13C respectively. The expression of these TFs show strong association with 
cancer and cancer related pathways specifically prostate cancer and thus demonstrates 
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that these genes can be assessed as possible biomarkers for prostate cancer. The 
prognostic and predictive values of the candidate genes were evaluated to assess their 
relationship to prognosis of this disease by means of several in silico prognostic 
databases. The results revealed expression differences for the majority of the candidate 
genes were not significantly sufficient to be distinguished as strong prognostic 
biomarkers in several prostate cancer populations. Although one marker, GP1BA was 
supported as having prognostic value for prostate cancer based on ???? statistical p-
value in one of the prostate cancer patient datasets used. Another candidate gene 
SEPT2 showed promise as it has some prognostic value in the early stages of the 
disease.  Although the results yielded, based on the in silico analysis, were not the 
discovery of an ideal diagnostic marker based on the set criteria in this study, further 
analysis using a molecular approach qRT-PCR can be considered for a detailed follow-
up study on selected candidate genes to evaluate their roles in disease initiation and 
progression of prostate cancer using cell lines as well as patient samples. 
Keywords: miRNA, gene expression, biomarker, STRING, Prostate-Specific Antigen, 
Bioinformatics  
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Chapter 1 
Literature Review 
1.1. Introduction 
Cancer is defined as a disease in which a group of abnormal cells grow uncontrollably 
by disregarding the normal rules of cell division. The foundation of modern cancer 
biology rests on a simple principle that virtually all mammalian cells share similar 
molecular networks that control cell proliferation, differentiation and cell death 
(Hejmadi, 2009). Cancer is a disease that involves changes or mutations in the cell 
genome and normal cells   are transformed into cancers as a result of changes in 
networks at the molecular, biochemical and   cellular level. Phenomenal advances in 
cancer research in the past 50 years have given insight into how cancer  cells develop 
(Hejmadi, 2009). 
Omics is the biomedical field describing the study in biology such as genomics and 
proteomics.   Many of the emerging fields of large-scale data-rich biology are 
??????????? ??? ??????? ???? ??????? ?-??????? ????? ??????????? ????? ???????????????? ??? ??
term referring to all the genes and the interactions of those genes with each other and 
the environment whereas proteomics refers to the study of proteins and its 
modifications made by an organism (Cho, 2007). Proteomics would not be possible 
without genomics. Therefore, in order to understand cancer biology there should be 
some understanding of molecular basis dealing with that of disease and proteomics for 
the discovery of biomarkers in complex diseases such as cancer (Cho, 2007).  
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In Bioinformatics, computational tools are applied on molecular data (genes and 
proteins) in a way to analyse and discover new outcomes by sequence recognition of 
genes and the prediction thereof. Genes are only the guidelines of the cell, while the 
proteins encoded by the genes are ultimately the functional drive for both normal and 
disease physiology. Cancer-related proteins and altered gene expression of miRNA, 
specifically in prostate cancer was the focus of this research, in order to identify 
biomarkers involved in prostate cancer development and progression thereof.  MiRNA 
molecules are already entering the clinic as diagnostic and prognostic biomarkers for 
patient stratification and also as therapeutic targets and agents (Jansson and Lund, 
2012). 
   1.2. Biology of cancer 
Cancer is a large group of diseases involving the uncontrolled growth and spread of 
abnormal cells that do not die, known as malignant tumours (Bashyam, 2002). Cancer 
is a multi-gene, multi-step disease originating from a single abnormal cell (clonal 
origin) with an altered DNA sequence (mutation).  Uncontrolled proliferation of these 
abnormal cells is due to successive rounds of mutation and selective expansion of 
these cells results in the formation of a tumour mass. These changes (DNA mutations) 
produce proteins that disrupt the delicate cellular balance between cell division 
resulting in cells that keep dividing to form cancers  (Hejmadi, 2009). 
Normal cells in the body have an orderly path of growth, division and death. Proteins 
within the cell control the cell cycle however cancer cells have an abnormal cell cycle 
and divide repeatedly out of control even though they are not needed; they crowd out 
normal cells and function abnormally (Bashyam, 2002). 
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1.3. Classification of cancer 
Cancer can be classified according to the type of cell that the tumour cells resemble 
which is likely to be the origin of the tumour (i) Carcinomas; are derived from 
epithelial cells such as breast, prostate and lung, (ii) Sarcomas; arising from connective 
tissue such as bone, cartilage and fat, (iii) Lymphomas; begin in the lymph nodes and 
immune system tissues and (iv) Leukaemia; begin in the bone marrow and accumulate 
in the blood stream.  Cancers are often referred to by terms that contain a prefix which 
is related to cell type the cancer originated from and a suffix such as ?sarcoma,-
carcinoma or ?oma. Some types of cancers are named according to the shape and size 
of the cells under a microscope such as small-cell carcinoma (International 
Classification of Diseases for Oncology, Third Edition - ICD-O-3). 
   1.4. The Cell cycle 
Most eukaryotic cells follow a process of growth and division called the cell cycle. 
These stages include; (1) a growth stage (2) mitosis or nuclear division and (3) 
cytokinesis or division of the cytoplasm. Throughout interphase the cell is engaged in 
growth and metabolic activities. Interphase can be broken down into three phases: G1, 
S and G2 (as seen in figure 1.1). During the G1 or first growth phase, normal cell 
function occurs as well as cell growth. S phase, DNA replicates producing two copies 
of each chromosome. G2 phase, the cell continues to prepare for mitosis and cell 
division. Mitosis or M phase has four stages. These phases are sequentially known as; 
prophase, metaphase, anaphase and telophase (Campbell and Reece, 2002). 
During prophase the chromosomes become visible and condense, becoming shorter 
and thicker. Each identical copy of a single chromosome is called a sister chromatid. 
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The nuclear envelope breaks down and spindle fibers form as microtubules grow out 
of the centrioles that move to opposite poles of the cell. During metaphase, the double-
stranded chromosomes line up along the equator of the cell. The microtubules attach to 
each sister chromatid (Campbell and Reece, 2002). Anaphase begins when the sister 
chromatids of each chromosome begin to separate (Campbell and Reece, 2002). The 
centromeres that hold the sister chromatids together divide and the chromosomes move 
away from each other along its spindle fiber. During telophase, the two groups of 
chromosomes reach the opposite ends of the cell, as a new nuclear envelope starts to 
form, the chromosomes uncoil and the spindle disappears. Cytokinesis or the C phase, 
involves the division of the cytoplasm and organelles. Two genetically identical cells 
are formed as a result of mitosis and cytokinesis (Campbell and Reece, 2002) 
  
Figure 1.1: The cell cycle (Taken from Campbell and Reece, 2002)  
1.5. Role of the cell cycle in cancer 
The study of these phases, the proteins that regulate them, and the complex 
biochemical interactions that stop or start DNA replication and cell division 
(cytokinesis) are the primary concerns of cell cycle biologists.   Many genes and 
proteins, that influence the passage from one phase of the cell cycle to another have 
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been identified and when their expression is altered by mutation or aberrant regulation, 
they are usually classed as oncogenes. Other proteins act to hold the cell at distinct 
points in the cycle (checkpoints) and are known as tumour suppressor genes. Most 
cancers are the result of inappropriate cell division, often stemming from aberrations in 
normal cell cycle regulation  (Kastan and Bartek, 2004). 
1.6. Regulation of the cell cycle 
How cell division (and thus tissue growth) is controlled is very complex. These 
regulatory molecules exist largely in two varieties: protein kinases, enzymes that serve 
to activate or inactivate other proteins through phosphorylation, and cyclins. Cdk 
(cyclin dependent kinase, adds phosphate to a protein), along with cyclins, are major 
control switches for the cell cycle, causing the cell to move from G1 to S or G2 to M 
phase (Carleton et al., 2007). Maturation Promoting Factor (MPF) includes the CdK 
and cyclins that triggers progression through the cell cycle. p53 is a protein that 
functions to block the cell cycle if the DNA is damaged. If the damage is severe this 
protein can cause apoptosis (cell death). p53 levels are increased in damaged cells 
(Carleton et al., 2007). This allows time to repair DNA by blocking the cell cycle. p53 
is frequently mutated in a number of cancers as an early genetic event. An extreme 
case of this is Li Fraumeni syndrome, where a genetic defect in p53 leads to a high 
frequency of cancer in affected individuals. p27 is a protein that binds to cyclin and 
Cdk blocking entry into S phase. Alteration of miRNA levels can also contribute to 
pathological conditions, including tumourgenesis,  that  are  associated  with  loss  of  
cell  cycle  control (Carleton et al., 2007). 
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Cell cycle checkpoints are regulatory pathways that control the order and timing of cell 
cycle transitions and ensure that critical events such as DNA replication and 
chromosome segregation are completed.  Checkpoints respond to damage by arresting 
the cell cycle to provide time for repair and by inducing transcription of genes that 
facilitate repair. Checkpoint loss, results in genomic instability and has been 
implicated in the evolution of normal cells into cancer cells  (Kastan and Bartek, 2004).  
Cyclins are among the most important components of the core cell cycle control 
system. Cyclins are a group of related proteins and there are four basic types: G1-
cyclins, G1/S-cyclins, S-cyclins and M-cyclins and each cyclin is associated with a 
particular phase, transition or set of phases in the cell cycle and helps drive the events 
of that phase or period (Kastan and Bartek, 2004). 
  
Figure 1.2: Mechanical analogy for the cell cycle control system (Taken from 
Campbell and Reece, 2002).    
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Checkpoints prevent cell cycle progression at specific points, allowing verification of 
necessary phase processes and repair of DNA damage. The cell cannot proceed to the 
next phase until checkpoint requirements have been met. Checkpoints typically consist 
of a network of regulatory proteins that monitor and dictate the progression of the cell 
through the different stages of the cell cycle. Several checkpoints are there to ensure 
that damaged or incomplete DNA is not passed on to daughter cells (Kastan and 
Bartek, 2004). 
1.7. Hallmarks of cancer 
All cancers share six common traits ("hallmarks") that govern the transformation of 
normal cells to cancer (malignant or tumour) cells.  The traits ("hallmarks") are (1) 
Cancer cells stimulate their own growth (self-sufficiency in growth signals), (2) they 
resist inhibitory signals that might otherwise stop their growth (insensitivity to anti-
growth signals), (3) they resist programmed cell death (evading apoptosis), (4) they 
can multiply indefinitely (limitless replicative potential), (5) they stimulate the growth 
of blood vessels to supply nutrients to tumours (sustained angiogenesis) and (6) they 
invade local tissue and spread to distant sites (tissue invasion and metastasis) 
(Hanahan and Weinberg, 2000). 
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Figure 1.3: The hallmarks of cancer (Taken from Hanahan and Weinberg, 2000) 
In an update published in 2011 ("Hallmarks of cancer: the next generation"), Weinberg 
and Hanahan proposed two new hallmarks: (1) abnormal metabolic pathways where  
most cancer cells use abnormal metabolic pathways to generate energy with the 
capability to modify, or reprogram, cellular metabolism in order to most effectively 
support neoplastic proliferation and (2) evading the immune system where  cancer cells 
??????? ??? ??? ?????????? ??? ???? ??????? ??????? ??????   allowing cancer cells to evade 
immunological destruction, in particular by T and B lymphocytes, macrophages, and 
natural killer cells (Hanahan and Weinberg, 2011). 
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Figure 1.4:  Two additional hallmarks of cancer are involved in the pathogenesis of 
some and perhaps all cancers (Hanahan and Weinberg, 2011). 
All normal cells have mechanisms that ensure errors or damages are detected within 
their own control systems. The tumour cells created by multiple mutations are able to 
push their way through the epithelial tissue's basement membrane, which are proteins 
that normally create a barrier (Hanahan and Weinberg, 2000). During the development 
of earlier stages of the tumour, angiogenesis takes place. Angiogenesis is the 
development of new blood vessels forming from the pre-existing vessels. With the new 
blood supply the growth of the tumour accelerates and individual cells from the 
tumour enter into the network of newly formed blood vessels using these blood vessels 
to move to other parts of the body. Most tumours are lethal due to their ability to 
metastasize (to establish new tumour sites at other locations throughout the body) 
(Hanahan and Weinberg, 2000).   
Metastasis is now underway, as tumour cells from the original cancer growth travel 
throughout the body (Bashyam, 2002). Invasion and metastasis are a dynamic multi-
step process. Most of these cells will die soon after entering the blood or lymph 
circulation. The tumour cell leaves the blood vessels and invades tissue.  While the 
 
 
 
 
10  
  
primary tumour may result from mutations in the growth control genes, metastasis 
probably results mainly from changes in gene expression patterns in the cell 
(Bashyam, 2002).  
1.8. Genetics of cancer 
Genetic changes occur at different levels and by different mechanisms. Most common 
mutations are changes in the nucleotide sequence of genomic DNA. Mutations include 
point mutations, deletions and insertions affecting the g?????? ??????? ????????? ????
altering the function of the genes protein product. Although complex error correction 
and prevention is built into each cell and tries to safeguard the cell against cancer, 
errors do occur and the control process fails, the mutation will survive and passed on 
to the daughter cells. Errors of mutations include (i) mutation in an oncogene causing 
the cell to reproduce faster, (ii) mutations might cause a loss of a tumour suppressor 
gene resulting in disruption of the apoptotic signalling pathway causing an immortal 
cell, (iii) mutations in the DNA damage and repair mechanisms will cause more errors 
in the daughter cells.   The transformation of a normal cell into cancer is a chain 
reaction caused by initial errors and mutations allowing the cell to escape the normal 
control mechanisms for normal cell growth. Once cancer has begun it is an on-going 
process of progression to more invasive stages (Merlo et al., 2006). 
Four types of genes are responsible for the cell division process playing a role in 
cancer development: (i) Oncogenes instructs the cell when to divide - promote cell 
growth and reproduction, (ii) Tumour suppressor genes instruct the cell when not to 
divide - codes for proteins that inhibit cell division (Croce, 2008). These are stated to 
be the two major genes that play a role in triggering cancer (Knudson, 2001), (iii) 
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Suicide genes or self-destruction genes control apoptosis (programmed cell death) and 
instruct the cell to kill itself if something goes wrong, (iv) The DNA in every cell in 
our body is constantly in danger of being damaged. DNA repair genes instruct the cell 
to repair damaged DNA.  
Several mutations need to occur to give rise to cancer. Cancer is caused by failure to 
regulate tissue growth, when the genes that regulate cell growth are altered (Croce, 
2008). Furthermore, epigenetic alterations are frequent in the DNA sequences coding 
for small RNAs called miRNAs. When oncogenes are expressed they are regulated by 
miRNAs. MiRNAs are small non-coding, single-stranded RNAs 21-25 nucleotides in 
length that control gene expression by downregulating them. Mutations in such 
miRNAs (known as oncomirs) can lead to activation of oncogenes. These alterations 
are caused by both DNA sequence mutation in oncogenes and tumour suppressor 
genes (Esquela-Kerscher et al., 2006). 
1.8.1 Epigenetic factors 
Although mutations are in the tumour suppressor genes, oncogenes and even 
chromosomal abnormalities, it has been found that cancer can also be driven by 
epigenetic alterations (Baylin et al., 2006). Epigenetics alterations are any functional 
modifications to the genome that does not involve any change to the nucleotide 
sequence (Kanwal et al., 2012). The epigenetic alterations serve to regulate gene 
expression without any change to the DNA sequence. According to various research 
studies, a large number of epigenetic alterations were found in cancers such as 
epigenetic alterations in DNA repair genes causing a reduced or silence expression of 
DNA repair proteins which results in deficient DNA repair (Jacinto et al., 2007, Lahtz 
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et al., 2011, Bernstein et al., 2013 and Bernstein et al., 2013). Like other cancers, 
prostate cancer occurs due to various genetic and epigenetic changes. 
1.9. Prostate cancer  
1.9.1. The prostate gland 
The prostate gland is divided into three zones: peripheral, transition and central zones 
(refer to figure 1.5). 
Peripheral zone 
This zone is the largest and closest to the rectum and therefore easily found during a 
digital rectum examination (DRE). The majority (about 70-80%) of prostate tumours 
originate in the peripheral zone (Basic principles 2010). 
 
Figure 1.5: Zones of the prostate gland affected by cancer  
(http://www.cancer.ca/~/media/CCE/1158/dc5c29f2337751c9e3038122fd0b3ed9.png) 
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Transition zone 
This is the middle area of the prostate gland, between the peripheral and central zones. 
When men age the transition zone enlarges and eventually becomes the largest area of 
the prostate and it is responsible for the disease of benign prostatic hyperplasia (BPH)  
(Basic principles 2010).  
Central zone 
Found in front of the transition zone and farthest from the rectum surrounding the 
ejaculatory ducts, accounting for about 2.5% of prostate cancers (Cohen et al., 2008).  
 
Figure 1.6: Anatomy of the prostate gland (American Cancer Society, 2015) 
1.9.2. Types of Prostate Cancer 
Carcinoma of the prostate (or prostate cancer) is the development of cancer in the 
prostate gland found in the reproductive system of the male. A healthy male prostate is 
a walnut-sized gland located below the urinary bladder surrounding the urethra, the 
tube that carries urine from the bladder during urination and semen during ejaculation 
(Moore et al., ????????????????????????????????????????????????????????????????????????????
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into cancer cells.  The prostate contains cells that make some of the fluid (semen) that 
protects and nourishes the sperm.  
Most prostate cancers are a type called adenocarcinomas, starting from the gland cells 
in the prostate. The type of cancer is found by sampling the cells from the prostate 
during a biopsy. Some types of prostate cancer include: (i) Ductal adenocarcinoma (ii) 
Transitional cell (urothelial) cancer (iii) Squamous cell cancer (iv) Carcinoid (v) Small 
cell cancer (vi) Sarcomas and sarcomatoid cancer (American Cancer Society, 2015). 
There are various conditions of the prostate that are non-cancerous: 
Benign Prostatic Hyperplasia (BPH) is a condition that causes the prostate to get larger 
as men age. BPH is not cancer and does not change into cancer. But it can cause 
problems urinating if the prostate gets larger. BPH is often treated with drugs that 
shrink the prostate or relax the muscles in it, which can help urine flow (Verhamme et 
al., 2002). 
In Prostatic Intraepithelial Neoplasia (PIN), there are changes in how the prostate 
gland cells look under the microscope, but ??????????????? metastasize, like cancer cells 
(American Cancer Society, 2015). 
Proliferative inflammatory atrophy (PIA) is another possible finding on a prostate 
biopsy. In PIA, the prostate cells look smaller than normal, and there are signs of 
inflammation. PIA is not cancer, but sometimes leads to high-grade PIN, or perhaps to 
prostate cancer (American Cancer Society, 2015). 
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1.10. Grading and staging of prostate cancer 
The system used most often for grading prostate cancer is called the Gleason scoring 
system. Samples from two areas of the prostate are each graded from 1 to 5, and the 
number grades are added to give a Gleason score or sum of between 2 and 10. Most 
biopsies have a Gleason score of at least 6. A higher score means the cells look less 
normal and the cancer is likely to grow more progressively. The stage (extent) of a 
cancer is one of the most important factors in determining treatment options and the 
outlook of recovery. The stage is based on the prostate biopsy results (including the 
Gleason score), the PSA level, and any other exams or tests that were done to assess 
how far the cancer has spread (BMJ Group, 2009).  
The TNM Staging System was developed and is maintained by the American Joint 
Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC)  
(Edge & Compton 2010). According to AJCC, TNM staging system is based on 5 key 
pieces of information: 
1. The extent of the main tumour (T category) 
2. Has the cancer spread to nearby lymph nodes (N category) 
3. Has the cancer metastasized (spread) to other parts of the body (M 
category) 
4. The PSA level at the time of diagnosis 
5. The Gleason score, based on the prostate biopsy (or surgery)  (American 
Cancer Society, 2015) 
These factors are combined to determine an overall stage, using Roman numerals i to 
iv (1 - 4). The lower the number, the less the cancer has spread. A high number, such 
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as stage IV (4), means a more advanced cancer (i) Stage I cancer is found only in the 
prostate and usually grows slowly (ii) Stage II cancer has not spread beyond the 
prostate gland, but involves more than one part of the prostate, and may tend to grow 
more quickly (iii) Stage III cancer has spread beyond the outer layer of the prostate 
into nearby tissues or to the seminal vesicles, the glands that help produce semen (iv) 
Stage IV cancer has spread to other areas of the body such as the bladder, rectum, 
bone, liver, lungs, or lymph nodes (AJCC). 
1.11. Epidemiology of prostate cancer 
Prostate cancer is the most common malignant tumour in men (Gronberg, 2003) and 
androgen-ablation therapy, the current management of advanced prostate cancer, 
reduces symptoms in about 70?80% of patients but do not provide a cure and most 
tumours relapse within 2 years resulting in and ultimately being responsible for 
prostate cancer mortality (Damber and Aus, 2008). Since 2012, prostate cancer is the 
most frequently diagnosed cancer (15% of all male cancers) and  with an estimated 
307,000 deaths in 2012, prostate cancer is the fifth leading cause of death from cancer 
in men (6.6% of the total deaths in men). PSA testing has a much greater effect on 
incidence than on mortality, there is less variation in mortality rates worldwide (ten-
fold from approximately 3 to 30 per 100,000) than is observed for incidence, 
[GLOBOCAN 2012 (IARC), Section of Cancer Surveillance (26/6/2016)] (Ferlay et 
al., 2014). 
Geography: Prostate cancer is most common in North America, North Western 
Europe, Australia, and the Caribbean, and it is less common in Asia, Africa, and 
Central and South America (Breslow et al., 1977). 
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Figure 1.7: Mortality and incidence rates of prostate cancer based on geographical 
location in males estimated age-standardised rates (World) per 100,000. 
Taken from: GLOBOCAN 2012 (IARC), Section of Cancer Surveillance (26/6/2016); 
World Cancer Report 2014). 
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Figure 1.8: Estimated Prostate Cancer Incidence Worldwide in 2012 Estimated age-
standardised rates (World) per 100,000 (GLOBOCAN 2012 (IARC) International 
Agency for Research on Cancer), WHO World Health Organization, 2015). 
  
Figure 1.9: Estimated Prostate Cancer Mortality Worldwide in 2012 Estimated age-
standardised rates (World) per 100,000(GLOBOCAN 2012(IARC) International 
Agency for Research on Cancer), WHO. World Health Organization, 2015). Risk 
factors of prostate cancer. 
 
 
 
 
19  
  
The global and region-specific estimates presented here and in more detail online 
(http://globocan.iarc.fr) provide a key resource for cancer researchers on the burden of 
cancer in 2012, and the cancer-specific patterns in 184 countries worldwide (Ferlay et 
al., 2014). 
1.12. Factors causing Prostate Cancer 
Epidemiology includes endogenous factors [family history, hormones, race, aging and 
oxidative stress] and exogenous factors [diet, environmental agents, occupation and 
other factors, including lifestyle factors] (Bostwick et al., 2004).   Epidemiologic 
studies have provided the greatest amount of information to date regarding risk of 
prostate cancer. However,   most of these studies have significant problems with 
exposure and disease characterization (Bostwick et al., 2004). 
Age: Prostate cancer risk goes up as men get older (Hankey et al., 1999).  Almost 6 
cases in 10 are diagnosed at the age of 65 years or later.  Age, especially 55 years and 
above had almost 17-fold higher risk of developing prostate cancer as compared to age 
less than 55 years (Bashir, 2015). 
Race: In the US, African-American men are more likely to get prostate cancer and die 
of it than in men of other races.  Differences in prostate cancer risk by race may reflect 
three factors: differences in exposure, such as dietary differences (exogenous factors); 
differences in detection (reflecting exogenous factors); and genetic differences 
(endogenous factors) (Bostwick et al., 2004).  African-Americans have the highest rates 
of prostate cancer in the world (223.0 per 100,000 men) (Bashir, 2015). 
Family history: Men with close family members (father or brother) who have had 
prostate cancer are more likely to get it themselves (Zeegers et al., 2003). 
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Men with a father or brother affected were twice as likely to develop prostate cancer as 
men with no relatives affected.   Increasing risk with increasing number of affected 
family members such that men with two or three first degree relatives affected had a 
five and 11?fold increased risk of developing prostate cancer (Steinberg et al., 1990, 
Bashir, 2015).  
Diet: Men who eat a lot of red meat or high-fat dairy products seem to have a greater 
chance of getting prostate cancer.   Fat consumption, especially polyunsaturated fat, 
shows a strong, positive correlation with prostate cancer incidence and mortality 
(Bostwick et al., 2004, Hayes et al., 1999). 
A small increased risk with lack of exercise is found in few cases of prostate cancer 
patients (Friedenreich et al., 2010). Obese men had almost six-fold higher risk of 
developing prostate cancer as compared to non-obese men  (Bashir, 2015). 
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1.13. Diagnosis of prostate cancer 
 
Figure 1.10: Progress of cancer in the prostate gland 
(http://www.prostateuk.org/psa/psa.htm) 
The widespread use of PSA screening has led to a dramatic downstaging of prostate 
cancer at diagnosis.   Prostate cancer is currently characterized by its clinical TNM 
stage, Gleason grade, and PSA serum level.   Imaging is becoming increasingly 
important in the assessment of prostate cancer since it can guide treatment selection, as 
well as treatment planning (Hricak et al., 2007). Imaging tests can determine if the 
cancer has spread. Microscopic spread of disease and early macroscopic invasion 
cannot be reliably shown using current technology (Heenan, 2004). There is no 
reliable and accurate test or imaging modality that can confidently diagnose and stage 
prostate cancer. A combination of digital rectal examination (DRE), prostate-specific 
antigen (PSA) level and transrectal ultrasound (TRUS) with systematic core biopsy 
and assessment of Gleason grade are used for diagnosis (Hricak et al., 2007). 
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? Magnetic resonance imaging (MRI)  offers the single most accurate assessment 
of local disease and regional metastatic spread of tumours.  Numerous studies 
have reported varying accuracies indicating that MRI is not the perfect imaging 
modality (Hricak et al., 2007). Currently MRI is not advocated for routine 
staging but it offers advantages over other imaging techniques in selected 
patients.   The use of MRI concluded that prostate cancer could not be 
differentiated from benign prostatic hyperplasia (BPH) and that its usefulness 
in staging was comparable to digital rectal examination (DRE) (Heenan, 2004).  
MR imaging, with high-resolution T2-weighted scans, MR spectroscopy, and 
dynamic contrast enhancement, is increasingly seen as a method that can 
improve prostate cancer detection, characterization, staging, and treatment 
follow-up (Hricak et al., 2007). 
? Computerized axial tomography scan (CAT scan) continues to be widely used 
in patients with newly diagnosed prostate cancer; it has virtually no role in 
prostate cancer detection or primary tumour staging. On CT scans, the 
separation between the prostate and the levatorani muscle is poorly defined, 
and intraprostatic anatomy is not well demonstrated.  The major role of CT is in 
the nodal staging of prostate cancer, for which it is limited   (Hricak et al., 
2007). 
? Prostatic ultrasound/ transrectal ultrasound (TRUS) is the most widely used 
clinical imaging method and it is the essential imaging tool for prostate cancer 
biopsy guidance. When prostate cancer is suspected, the diagnostic test of 
choice is a systematic needle biopsy with ultra sound guidance.  Even with such 
systematic sampling, underdiagnosis of the extent of prostate cancer can occur 
with transrectal ultra sound-guided biopsy  (Hricak et al., 2007). 
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Cancer screening is an examination to detect cancer before a person has symptoms. 
The American Cancer Society recommends screening for early detection, particularly 
for high-risk people or people with symptoms. Diagnosis is confirmed by various 
methods - clinical (physician) examination, laboratory testing (PSA test), scans (MRI, 
CAT), DRE (digital rectal examination) and transrectal ultrasound (TRUS).   Precise 
indications for and sensitivity and specificity of conventional imaging methods such as 
radionuclide bone scanning, computed tomography (CT), magnetic resonance (MR) 
imaging, ultrasonography (US), and combined positron emission tomography 
(PET)/CT remain under debate (Hricak et al., 2007). 
1.14. Prostate-specific antigen  
PSA is a protein produced by the cells of the prostate gland. PSA is found in the blood 
and measured in nanograms of PSA per millilitre (ng/mL) of blood. As seen in figure 
1.10, increased PSA levels are found in the blood of men with prostate cancer. The test 
is used to monitor the progression of prostate cancer. PSA is one of the best-known 
biomarkers in medicine but due to its insufficient specificity, researchers are looking at 
tests based on several biomarkers. PSA testing increases cancer detection but does not 
decrease mortality (Djulbegovic et al., 2010). Small cell carcinoma is a rare type of 
prostate cancer that is serious and spreads quickly to other parts of the body and cannot 
be detected using the PSA test thus various other biomarkers are necessary to detect 
these kinds of rare and hidden cancers (Nutting et al., 1997; Wei et al., 2009). 
PSA level is a strong indicator of stage and prognosis and is helpful in monitoring 
response to therapy. However, absolute PSA serum levels must be interpreted carefully 
with regard to the age of the patient, the size of the gland, and the presence of infection  
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(Hricak et al., 2007).  PSA was first used by forensic scientists as a marker for human 
semen. In the late 1970s, the initial laboratory studies were conducted to evaluate the 
relationship between PSA and prostatic disease (Loeba and Catalonab, 2007).    
In 1986, the U.S. Food and Drug Administration (FDA) approved the PSA test for 
prostate cancer screening. In the late 1980s the first clinical studies were initiated to 
examine the role of PSA in prostate cancer screening. Previously, most prostate cancer 
cases were diagnosed either through a suspicious digital rectal examination (DRE) or 
as an incidental finding in the prostate chips from transurethral resection for presumed 
benign prostatic hyperplasia (BPH)  (Loeba and Catalonab, 2007).    
There are several problems that complicate its use in daily practice. Firstly, PSA can 
also be elevated in benign prostatic conditions, limiting its specificity for prostate 
cancer. Even certain medications (e.g., Finasteride), ejaculation, and prostate 
manipulation (e.g., catheterization, cystoscopy, and prostatic massage) can alter PSA 
levels. The concerns about overdiagnosis of prostate cancer have become increasingly 
more resonant (Loeba and Catalonab, 2007)  ????????  unlikely that PSA by itself will be 
an effective screening tool for the early diagnosis of prostate cancer. However, if 
combined with digital rectal examination and/or transrectal ultrasound it is a vital part 
of any early detection program.   Conditions such as bacterial prostatitis and acute 
urinary retention can also falsely elevate the serum PSA level. Approximately 25% of 
the patients with BPH will have an elevated serum PSA concentration.   Prostatic 
intraepithelial neoplasia may also be associated with moderately elevated serum PSA 
levels (Oesterling, 1991). 
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1.15. Biomarkers 
1.15.1. What are Biomarkers? 
A biomarker is a gene, protein/peptide or metabolite present in a biological system, 
used to indicate a physiological or pathological state that can be recognized or 
monitored (Azuaje, 2010). 
Biomarkers are used to measure the progress of disease or the physiological effects of 
therapeutic intervention in the treatment of disease. The utility of a biomarker lies in 
its ability to provide an early indication of the disease, to monitor disease progression, 
to provide ease of detection and to provide a factor measurable across populations 
(Srinivas et al., 2002).   A practical serological biomarker should have certain 
characteristics, i.e. it is a secreted or shed protein and has the ability to diffuse into the 
circulation during tumour development and progression, through either angiogenesis 
or invasion of surrounding tissues and vasculature by cancer cells (Diamandis, 2004). 
Biomarkers can be proteins, metabolites, RNA transcripts, DNA, or epigenetic 
modifications of DNA, among other alterations. They can be detected through patient 
tissue samples, obtained either by biopsy or surgical resection, or non-invasively 
through the isolation of cells and/or molecules from bodily fluids, such as blood or 
urine (Prensner et al., 2012).  
1.15.2. Types of Biomarkers 
Promising biomarkers should be overexpressed proteins but this is not generally true 
for some of the best known cancer biomarkers such as PSA (Diamandis, 2004). 
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On the basis of their application to the detection of disease, three main classes of 
biomarkers may be specified: screening, diagnostic and prognostic biomarkers. 
Screening biomarkers are used to predict the potential occurrence of a disease in 
asymptomatic patients. Diagnostic biomarkers are used to make predictions on patients 
suspected of having the disease. Prognostic biomarkers are applied to predict the 
outcome of a patient suffering from a disease. Molecular biomarkers are measured in 
biological samples: solid tissues, blood or other bodily fluids (Azuaje, 2010). 
1.15.3. Methods to discover Biomarkers 
Biomarker discovery is a challenging process and a good biomarker has to be 
sensitive, specific and its test highly standardized and reproducible as well as identify 
risk for or diagnose a disease, assess disease severity or progression, predict prognosis 
or guide treatment. Biomarker discovery is a major research field of differential omics. 
It is a process of discovery, verification and validation. During the discovery and 
validation process there should be insight into the understanding of the molecular 
mechanism of the diseases (Azuaje, 2010). 
Biomarker verification is done in two ways: 
I. Wet-lab verification - Sample processing molecu???? ????????? ????? ???????????
hypotheses. 
II. Computer-based techniques (Bioinformatics) - Data pre-processing, feature 
extraction and selection, statistical analysis, predictive modelling and refined / 
new hypotheses (Azuaje, 2010). 
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1.16. Biomarkers currently used for prostate cancer diagnosis  
For early diagnosis, it is best to find a non-invasive cancer biomarker to monitor 
molecular differences in tumours thus assisting in better treatment for cancer patients. 
A cancer biomarker, prostate-specific antigen (PSA), is a protein found in the blood of 
adult men with prostate cancer (Makarov et al., 2009).  
Prostate acid phosphatase (PAP) was the first reported biomarker to be elevated in the 
serum of patients with prostate cancer in 1930s (Gutman AB et al., 1938). However, 
PAP proved to be insensitive to detect localized lesion of prostate cancer and was 
replaced by PSA that was discovered in 1970 (Makarov et al., 2009). The low 
specificity of PSA in detecting prostate cancer caused relative high false? positive rate 
in screening (Makarov et al., 2009). 
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Figure 1.11: Classification of biomarkers in prostate cancer (Ludwig JA et al., 2005). 
As new biomarkers are discovered, the following are needed in prostate cancer 
biomarker discovery; validating the many existing prostate biomarkers already 
discovered; (i) developing markers to minimize the number of unnecessary prostate 
biopsies. (ii) developing markers to identify men with indolent prostate cancer who 
will not be affected by disease in their lifetimes and do not need treatment. (iii) 
developing markers to identify men with aggressive disease who will benefit from 
local therapy and those who are likely to fail local therapy and require adjuvant 
intervention and (iv) developing markers that may serve as surrogate endpoints for 
clinical progression or survival (Makarov et al., 2009).    
Future research can focus on validation of already existing biomarkers and the 
discovery of new markers to identify men with aggressive prostate cancer 
(Baumgartner et al., 2011).  miRNAs has come to the fore to that it necessitates closer 
inspections as prostate cancer biomarkers. 
Biomarker
DNA-­‐based  
markers
RNA-­‐bases  
markers protein  markers
Tissue  markers  
(AMACR,  
methylated  GSTP1  
and  TMPRSS2-­‐ETS  
gene)
Serum  markers  
(PAP,tPSA,  fPSA,  
pro  PSA,  PSAD,  
PSAV,  PSADT,  EPCA  
and  EPCA-­‐2)
Urine  marker
(DD3PCA3/UPM-­‐3)
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1.17. MiRNAs activity 
MiRNA are regulatory RNA which play a role in gene expression. MiRNAs do not 
code for proteins, but can "target" protein-coding genes and reduce their expression. In 
mutations, the expression of the miRNAs of the genes it regulates is misexpressed 
resulting in cancer. Altered miRNA expression or the target genes thereof may serve 
as a biomarker for cancer diagnosis and treatment. Circulating miRNAs found in the 
blood of cancer patients has raised the possibility that miRNAs can serve as a novel 
diagnostic biomarker (Kosaka et al., 2010). 
The miRNAs play a role in physiological and pathological processes, such as 
development, cell proliferation, apoptosis and stress responses (Bartel, 2004). A single 
miRNA is said to target several mRNAs and in this sense if there are mutations in the 
miRNA expression then the expression of several mRNAs and proteins are also 
disrupted. In various studies, researchers have shown that measuring different miRNA 
levels in serum demonstrated that they could distinguish patients with cancer from 
healthy individuals (Lawrie et al., 2008, Mitchell et al., 2008).  
1.18. MiRNAs and its target genes/proteins as diagnostic biomarkers  
MiRNA suppress the expression of oncogenes, growth promoting, survival and 
angiogenic genes (low in tumours). MiRNA suppress expression of tumour suppressor, 
growth inhibitory and proapoptotic genes. A select number of miRNAs may serve as 
diagnostic markers or even potential therapeutic targets for different tumour types as 
several miRNAs are up-or down-regulated in multiple tumours (Sevli et al., 2010). 
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MiRNAs has critical functions in gene expression and dysregulation may cause tumour 
formation and progression. When miRNAs are up-regulated it inhibits tumour 
suppressor genes in tumour cells (Sevli et al., 2010) and are known as oncogenic 
miRNAs or oncomirs whereas the miRNAs that are down-regulated causing tumour 
progression are tumour suppressor miRNAs. The reduced expression is a result of 
increased levels of oncogene expression (Sevli et al., 2010).  
miRNAs regulate gene expression by direct cleavage of the targeted mRNAs or 
inhibiting translation through perfect or nearly perfect complementarity to targeted 
mRNAs. These targeted genes control multiple biological processes, including stem 
cell division, apoptosis and cancer (Zhang et al., 2007). 
miRNAs with high influence on protein networks are valuable biomarkers that can be 
used in clinical investigations for cancer treatment. Over- or under-expression of 
specific miRNAs in different tumours makes them potential diagnostic or prognostic 
biomarkers, however, miRNAs that are differentially expressed and influence their 
targets and target partners are important regulators and thus are more promising for 
diagnostics, prognostics or therapy (Alshalalfa et al., 2012). 
1.19. Bioinformatics ? a search tool for biomarker discovery 
Computational approaches are effective for the detection of potential miRNAs in 
cancer. Biomarker discovery for prostate cancer of mRNA and microRNA expression 
are strongly needed to enable more accurate detection of prostate cancer, improve 
prediction of tumour aggressiveness and facilitate diagnosis. Computational biology 
(bioinformatics) plays a significant role in the discovery of new biomarkers, the 
analyses of disease states and the validation of potential biomarkers (Srinivas et al., 
2002). 
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Bioinformatics is crucial in the analysis of functional genomics data such as data 
clustering or principal component analysis. Functional enrichment analysis is used to 
determine the extent of over- or under-expression of functional categories relative to a 
background sets (Subramanian et al., 2005). Functional genomics describes the use of 
large scale data produced by high throughput technologies or databases to understand 
the function of genes and other parts of the genome (Narayanan, 2007). 
 Bioinformatics, such as digital differential display and in silico Northern blotting is 
used to compare gene expression between normal and cancerous tissues to identify 
overexpressed genes (Diamandis, 2004). 
This technology is the key to understanding and management of biological information 
and is essential to use the genomic information in understanding human diseases. 
There is growth in biological data due to the numerous amounts of research being done 
in the molecular field. Large databases are available, accessible and analysed for 
biological research and education. Prediction of a sequence (what we know), we can 
???????? ?????????????????? ????????? ?????????????????????????????????????? ?????????? ???
compared with related proteins and proteins with similar sequences (Baumgartner et 
al., 2011). 
 In general, the search, verification, biological and biochemical interpretation and 
independent validation of disease biomarkers require new innovations in high-
throughput technologies, biostatistics and bioinformatics and thus make necessary the 
interdisciplinary expertise and teamwork of clinicians, biologists, analytical- and 
biochemists and bioinformaticians to carry out all steps of a biomarker cohort study 
with professional planning, implementation, and control. Bioinformatics plays a key 
role in the biomarker discovery process, bridging the gap between initial discovery 
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phases such as experimental design, clinical study execution, and bioanalytics, 
including sample preparation, separation and high-throughput profiling and 
independent validation of identified candidate biomarkers (Baumgartner et al., 2011). 
  
Figure 1.12:  Tools for discovery and validation of biomarkers (Baumgartner et al., 
2011). 
1.20. Conclusion  
There is a need to develop new biomarkers for prostate cancer and this project is an 
attempt to identify effective biomarkers for prostate cancer using bioinformatics with 
the goal of finding more specific biomarkers to avoid overdiagnosis and overtreatment 
associated with PSA screening of prostate cancer. No individual marker is ideal but 
further validation of promising markers and continued discovery of biomarkers is 
needed. Even a combination of biomarkers should improve the predictive accuracy and 
using protein-protein interaction network for prostate cancer should hopefully help 
improvement in clinical outcome.  
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1.21. Aims and objectives  
The aim of this study was to identify prostate specific biomarkers for early diagnosis 
of the disease using in silico methods.    
Objectives: 
1. Identifying co-expression genes/proteins of 21 genes regulated by 13 miRNAs in 
prostate cancer. 
2. Extracting and refining a gene list from various databases for identifying potential 
biomarkers as diagnostic molecules for prostate cancer. 
3. Associate the candidate gene list to transcription factors to confirm their regulatory 
control in cancer processes and specifically prostate cancer. 
4. Assess the association of the candidate genes to pathways that contribute to the 
outcome of prostate cancer for better and supportive diagnostic evaluation. 
5. Evaluate the Prognostic and Predictive value of the candidate genes to assess their 
usefullness in the prognosis of prostate cancer. 
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Chapter 2 
Generation of a putative gene list for the early diagnosis of prostate cancer using a 
bioinformatics approach 
2.1. Introduction 
The National Center for Biotechnology Information defines Bioinformatics as:  
Bioinformatics is the field of science in which biology, computer science, and information 
technology merge into a single discipline. There are three important sub-disciplines within 
Bioinformatics: the development of new algorithms and statistics with which to assess 
relationships among members of large data sets; the analysis and interpretation of various 
types of data including nucleotide and amino acid sequences, protein domains and protein 
structures and the development and implementation of tools that enable efficient access and 
management of different types of information (NCBI, 2001). 
As a complex disease, cancer is related to a large number of genes and proteins. Biomedical 
researchers are interested in data-mining literature based on cancer-related genes and proteins 
to study cancer diagnostics, treatment, and prevention (Zhu et al., 2012). 
Existing scientific literature represents a rich source of knowledge based on the associations 
between genes, diseases and cellular processes.   The biomedical literature is an important 
source of knowledge on the function of genes and on the mechanisms by which these genes 
regulate cellular processes (Frijters et al., 2010). 
Owing to the increasing body of text and the open-access policies of many journals, literature 
mining is also becoming useful for both hypothesis generation and biological discovery. 
However, the biological discovery will require the integration of literature and high-
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throughput data, which should encourage close collaborations between biologists and 
computational linguists (Jensen et al., 2006). 
Cancer remains a major public health challenge despite progress in detection and therapy 
(Srinivas et al., 2002).  Among the important tools critical to detection, diagnosis, treatment, 
monitoring, and prognosis are biomarkers (Srinivas et al., 2001). Bioinformatics tools are 
essential in the discovery of sensitive and specific biomarkers in cancer research (Srinivas et 
al., 2002).  
Unlike benign prostate hyperplasia (BPH) or prostatitis, prostate cancer may not give 
symptoms in its early, curable stage, and therefore it is often diagnosed in the advanced 
stages of the disease. An intervention at an early stage may reduce the progression of small 
localized carcinoma to a large metastatic lesion, thereby reducing prostate cancer-related 
deaths. Discovery of other biomarkers are needed, if improvements in diagnosis and 
prognosis of prostate cancer are to be realized (Adam et al., 2001).  One of the best ways to 
diagnose cancer early, aid in its prognosis, or predict therapeutic response, is to use serum or 
tissue biomarkers (Kulasingam, 2008).  Cancer biomarkers can be DNA, mRNA, proteins, 
metabolites, or processes such as apoptosis, angiogenesis or proliferation (Hayes et al., 
1996).  Powerful bioinformatics tools, has a direct and major impact on the way the search for 
cancer biomarkers is conducted.  The modern technologies are capable of performing parallel 
rather than serial analyses and they can help to identify distinguishing patterns and multiple 
markers rather than just a single marker; such strategies represent a central component and a 
paradigm shift in the search for novel biomarkers (Kulasingam, 2008). 
Prostatic carcinomas most often arise in the glandular epithelium of the prostate periphery. 
Although PSA (KLK3) gene transcription is down-regulated in prostate cancer, PSA protein 
levels in the circulation of patients with prostate cancer increase through disruption of the 
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anatomic barriers between the glandular lumen and capillaries. Concomitant to early-stage 
prostate cancer is the loss of basal cells, disruption of cell attachment, degradation of the 
basement membrane, initiation of lymphangiogenesis. A goal of finding more specific 
biomarkers to avoid over-diagnosis and overtreatment associated with PSA screening of 
prostate cancer (Stacker et al., 2002). 
Ideally, a cancer biomarker should be detectable in the blood or other body fluids that can be 
accessed in a non-invasive manner and none has met the original goal of discovering cancer 
at an early stage. One reason for the low sensitivity and specificity is the presence of these 
markers in the serum of individuals without cancer or with non-malignant disease. Many 
potentially valuable biomarkers are expressed at very low levels and are difficult to detect. 
Finding new and better methods for detecting and identifying these low-abundant proteins 
represents a new challenge for routine diagnostics (Seibert et al., 2005). 
????? ???? ?????? ??????? ?????????? ??????????? ??? ????? ???? ????? ??????????? ???????? ???
expression data becoming available, growing attention is being paid to in silico biology. 
Broadly speaking, the term in silico biology refers to the use of computers to perform 
biological studies and a high-throughput experimental technology which is generating 
biological data at unprecedented rates and the pace will only accelerate. The bioinformatics 
infrastructure that tabulates, curates and makes these data retrievable is developing in parallel 
(e.g., WIT, EcoCyc, MIPS, KEGG, Biology WorkBench, EMP, and Swiss-Prot) (Palsson, 
2000). 
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2.2. Computational approaches to predict a novel biomarker 
2.2.1. Data mining 
The overall goal of the data mining process is to extract information from a data set and 
transform it into an understandable structure for further use. Data mining is the analysis step 
of the "Knowledge Discovery in Databases" process, or KDD (Fayyad et al., 1996). 
A particular active area of research in bioinformatics is the application and development of 
data mining and techniques to solve biological problems. Analysing large biological data sets 
requires making sense of the data by inferring structure or generalizations from the data. 
Examples of this type of analysis include protein structure prediction, gene classification, 
cancer classification based on microarray data, clustering of gene expression data, statistical 
modelling of protein-protein interaction, etc. (Raza 2012). 
2.2.2. Biomedical text mining 
Biomedical text mining (also known as BioNLP) refers to text mining applied to texts and 
literature of the biomedical and molecular biology domain. It is a rather recent research field 
on the edge of natural language processing, bioinformatics, medical informatics and 
computational linguistics.   The main developments in this area have been related to the 
identification of biological entities (named entity recognition), such as protein and gene 
names as well as chemical compounds and drugs. Information extraction and text mining 
methods have been explored to extract information related to biological processes and 
diseases (Krallinger et al., 2010). 
There have been an enormous number of publications on cancer research. This integrated but 
unstructured biomedical text is of great value for cancer diagnostics, treatment, and 
prevention. The immense body and rapid growth of biomedical text on cancer has led to the 
appearance of a large number of text mining techniques aimed at extracting novel knowledge 
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from scientific text. Biomedical text mining on cancer research is computationally automatic 
and high-throughput in nature (Zhu et al., 2012).   Text mining can aid in uncovering 
information and knowledge from a mountain of text and it is now widely applied in 
biomedical research (Zhu et al., 2012). 
Text Mining is an information retrieval task aimed at discovering new, previously unknown 
information, by automatically extracting it from different text resources.   Research and 
development in the analysis of bioinformatics literature aims to provide bioinformaticians 
with effective means to access and exploit the knowledge contained in scientific publications 
(Manconi et al., 2012). 
2.2.2.1. PubMed 
Hands-on literature mining currently means a keyword search in PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed) or any literature database. In terms of information 
retrieval systems, PubMed is one of the best known biomedical databases and it contains 
more than 20 million citations on biomedical articles from MEDLINE and life science 
journals, which provides a convenient web-based search portal for users as well as an 
application program interface for developers (McEntyre et al., 2001). 
PubMed is a database developed by NCBI National Library of Medicine (NLM), it works as 
a part of the NCBI Entrez retrieval system, primarily designed to provide access to references 
and abstracts from biomedical and life sciences journals. PubMed provides links that allow 
access to the full-text journal articles of participating publishers (Lindberg, 2000).  PubMed 
remains an optimal tool in biomedical electronic research (Falagas, 2008). 
2.2.2.2. Google scholar 
Google Scholar (http://scholar.google.com) enables the user to search specifically for 
scholarly literature, including peer-reviewed papers, theses, books, preprints, abstracts and 
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technical reports from all broad areas of research. Google Scholar is used to find articles 
from a wide variety of academic publishers, professional societies and universities and 
available across the web. Google Scholar provides a new method of locating potentially 
relevant articles on a given subject by identifying subsequent articles that cite a previously 
published article (Noruzi, 2007). 
2.2.3. Biological databases  
Biological databases are libraries of life sciences information, collected from scientific 
experiments, published literature, high-throughput experiment technology and computational 
analysis (Attwood et al., 2012). 
Biological databases represent an invaluable resource in support of biological research. Much 
can be learned about a particular molecule by searching various databases and using available 
analysis tools. A large number of databases are available for that task and some databases are 
general while some are much specialised. For best results one often need to access multiple 
databases. Biological database design, development and long-term management are a core 
area of the discipline of Bioinformatics (Bourne, 2005). 
2.2.3.1. STRING 
Interactions between proteins are very important to understand their functions and biological 
processes. Several approaches and tools have been defined to deal with this challenge 
(Manconi et al., 2012). The STRING (Search Tool for the Retrieval of Interacting 
Genes/Proteins) database (http://string-db.org) aims to provide a critical assessment and 
integration of protein?protein interactions, including direct (physical) as well as indirect 
(functional) associations. The new version 10.0 of STRING covers more than 2000 
organisms, which has necessitated novel, scalable algorithms for transferring interaction 
information between organisms (Szklarczyk et al., 2014).  STRING characterises functional 
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links between proteins and the protein network, i.e. the summary of all known or predicted 
protein interactions in an organism.  
STRING specializes in three ways: (i) it provides uniquely comprehensive coverage, with 
>2000 organisms, 5 million proteins and >200 million interactions stored; (ii) it is one of very 
few sites to hold experimental, predicted and inferred interactions, together with interactions 
obtained through text mining; and (iii) it includes a wealth of accessory information, such as 
protein domains and protein structures, improving its day-to-day value for users.  Protein?
protein associations have proven to be a useful concept, by which to group and organize all 
protein-coding genes in a genome (Franceschini, 2013). The confidence score is the 
approximate probability that a predicted link exists between two enzymes in the same 
metabolic map in the KEGG (Kyoto Encyclopedia of Genes and Genomes) database. 
Confidence limits are as follows: low confidence - 20% (or better), medium confidence - 
50%, high confidence - 75%, highest confidence - 95% (Szklarczyk et al., 2010). STRING 
quantitatively integrates interaction data from these sources for a large number of organisms, 
and transfers information between these organisms. The database currently covers 9'643'763 
proteins from 2'031 organisms (Szklarczyk et al., 2015). 
2.2.3.2. DAVID 
DAVID (Database for Annotation, Visualization, and Integrated Discovery) 
(http://david.abcc.ncifcrf.gov/) is a web-accessible program that integrates functional 
genomic annotations with intuitive graphical summaries. Lists of gene or protein identifiers 
are rapidly annotated and summarized according to shared categorical data for Gene 
Ontology, protein domain, and biochemical pathway membership (Dennis, 2003).  The 
DAVID database aims to provide functional interpretation of large lists of genes and to 
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analyse these gene lists derived from high-throughput genomic experiments (Huang et al., 
2009). 
2.2.3.3. Gene Ontology 
The Gene Ontology tool (GO) (http://www.geneontology.org)   consists of a collaborative 
????????????????????????????????????????????????????????????????????????????????????????????????
cellular location of action (Gene Ontology Consortium, 2012). 
The discipline of ontology allows experimental data to be stored in such a way that it 
constitutes a formal, structured representation of the reality captured by the underlying 
biological science. Ontology of a given domain represents types and the relations between 
them, and is designed to support computational reasoning about the instances of these types 
(Hill, 2008). GO resources include biomedical ontologies that cover molecular domains of all 
life forms as well as extensive compilations of gene product annotations to these ontologies 
that provide largely species-neutral, comprehensive statements about what gene products do 
(Blake, 2013). 
An enrichment analysis is performed directly from the home page of the GOC website. This 
service connects to the analysis tool from the PANTHER Classification System, which is 
maintained up to date with GO annotations.   The PANTHER (protein annotation through 
evolutionary relationship) classification system (http://www.pantherdb.org/) is a 
comprehensive system that combines gene function, ontology, pathways and statistical 
analysis tools that enable biologists to analyse large-scale, genome-wide data from 
sequencing, proteomics or gene expression experiments (Mi et al., 2013). 
2.2.3.4. TiGER 
Most of currently available biological databases do not focus on tissue-specific gene 
regulation but a web database called TiGER (Tissue-specific Gene Expression and 
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Regulation) (http://bioinfo.wilmer.jhu.edu/) house data on several genes across various 
tissues. The database contains three types of data including tissue-specific gene expression 
profiles, combinatorial gene regulations, and cis-regulatory module (CRM) detections. The 
database provides three views (gene view, transcription factor view, and tissue view) to allow 
users to conveniently retrieve information about genes, TFs or tissues of interest. TiGER 
provides visualizations of the gene expression profiles, TF interactions and CRM detections 
(Liu et al., 2008).  
2.2.3.5. GeneHub-GEPIS 
GeneHub-GEPIS (http://research-public.gene.com/Research/genentech/genehub-
gepis/index.html) is a web server useful tool for performing gene expression analysis across 
many normal and cancer tissues for both mouse and human genes (Zhang, 2007). One 
distinguishing characteristic of this tool is that ESTs are mapped to pre-defined gene 
structures along the genome. 
GeneHub-GEPIS can report estimated expression levels in about 40 different types of normal 
and cancerous tissues for a given gene or a list of genes.  This tool is built upon the previous 
GeneHub database, which integrates gene and protein information from several databases 
(Zhang, 2007). 
2.3. Previous Study  
Using a bioinformatics framework as well as a molecular approach,  21 genes regulated by 13 
miRNAs were identified in a previous study (Khan, PhD thesis, 2015) as potential Prostate 
cancer miRNA targets. 
The 13 miRNAs were analysed using Real-Time PCR (qPCR) using a panel of prostate 
cancer cell lines as well as a panel of various cancer cell lines to determine the specificity of 
these miRNAs for prostate cancer as potential diagnostic biomarkers. This work focused on 
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the miRNA regulated genes to create a candidate gene list for prostate cancer diagnosis as 
well as prognosis. Thus a combination of miRNAs and protein biomarkers can be used to 
specifically and sensitively diagnose prostate cancer at its early stages as well as monitor 
outcome to treatment (prognosis).  
Table 2.1: 21 miRNA target genes that were identified by computational prediction methods 
as candidate biomarkers for detection of prostate cancer. 
 
2.4. Aims 
1. Expand on the current list of 21 genes. 
2. Extract and refine a list of genes as possible potential biomarkers for early diagnosis 
of prostate cancer, using the various databases outlined above. 
3. Confirm the candidate genes as novel to prostate cancer and generate a manageable 
candidate gene list. 
Target Gene description MiRNA related with target 
TMX1 Theoredoxin-related transmembrane protein MiR 10
TNFSF15 Tumor necrosis factor (ligand) superfamily, member 15 MiR 11
LIG4 Ligase IV, DNA, ATP-dependent MiR 12
FOXC1 Forkhead box C1 MiR 13
MNT MAX binding protein MiR 13
YWHAZ
Tyrosine 3-monooxygenase/ tryptophan  5-monooxygenase activation protein, zeta 
polypeptide MiR 9
TNFSF13B Tumour necrosis factor MiR 9
ADNP Activity-dependent neuroprotector homeobox MiR1
PAK7 p21 protein (Cdc42/Rac)-activated kinase 7 MiR1
RAB27A RAB27A, member RAS oncogene family MiR1
ACVR1C Activin A receptor, type IC MiR1
BTG2 BTG family member 2 MiR2
SH3RF1 SH3 domain containing Ring Finger MiR3
BFAR Bifunctional Apoptosis regulator miR3
PRKCI Protein kinase C, iota MiR4
PTPRC Protein tyrosine phosphatase, receptor type, C MiR4
ING4 Inhibitor of growth family, member 4 MiR5
ATM Ataxia telangiectasia mutated MiR6
CLN8 Ceroid-lipofuscinosis, neuronal 8 MiR7
CFLAR CASP8 and FADD-like apoptosis regulator MiR8
CSRNP3 Cysteine-serine-rich nuclear protein 3 MiR8
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2.5. Materials and methods 
  
Figure 2.1: Outline of Methodology for generation of a candidate gene list 
2.5.1. Expansion of candidate gene list 
2.5.1.1. Identification of co-expressed genes using the STRING database 
The STRING database was accessed at (http://string-db.org) and the 21  miRNA target genes 
were individually used in STRING to generate a list for each gene of co-expressed known 
and predicted protein-protein interactions. Input query of gene/protein name included 
organism of Homo sapiens as the species of interest. Predicted functional partners were 
derived from four sources: Genomic context, high-throughput experiments, co-expression 
and previous knowledge (PubMed etc.). Active Prediction Methods included neighborhood, 
gene fusion, co-occurrence, co-expression, experiments, databases and text mining as 
parameters.  
The default settings and additional criteria used were as follows: High confidence score 
(0.700) of 20   protein-protein interactions and a medium confidence score (0.400) with 10 
Expansion of the list of 21 genes by identifying 
their co-expressed genes using STRING
Eliminate duplication of genes and identify cell 
surface gene products using GO database 
Confirm generated gene list by functional 
annotation clustering in DAVID database to be 
associated with cancer 
Literature mining to cross reference gene lists 
against biological databases to identify previously 
non-associated prostate cancer genes
Candidate list of genes
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interactions. These settings were used as a stringency measure to filter the number of 
interactions that will be produced at a lower confidence score. Interactions found for each 
gene equals the amount of genes/proteins identified. 
Further refinement of the identified co-expressed genes by elimination of duplication and 
overlapping of genes was performed; this gene list was used further to generate a manageable 
candidate gene list using additional bioinformatics tools. 
2.5.1.2. Gene Ontology based enrichment analysis  
Enrichment analysis was done on the gene set generated in the previous section, by inserting 
all gene names one per row and  selecting the species; Homo sapiens. The ontology, cellular 
component was used to calculate the enrichment for genes corrospondng to a particlar term.  
Criteria: GO terms relating to the cellular component (CC) parts of a cell or its extracellular 
environment (e.g. cytoplasm, integral to plasma membrane) were used to further refine the 
list of genes. Ontology criteria included cell surface and displaying only the results with 
P<0.05. 
Analysis Summary of GO 
Analysis Type: PANTHER Overrepresentation Text  
Annotation Version and Release Date: GO Ontology database  
Analyzed List: upload_1 (Homo sapiens) 
Reference List: Homo sapiens (all genes in database) 
Annotation Data Set: GO cellular component complete 
The Bonferroni correction for multiple testing was used. The Bonferroni correction is 
important because many statistical tests are performed (one for each ontology term) at the 
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same time. This correction multiplies the single-test P-value by the number of independent 
tests to obtain an expected error rate  (Thomas et al., 2016). 
2.5.1.3. Functional Annotation clustering using DAVID 
DAVID database was accessed as a confirmation of results obtained from GO analysis. All 
genes were submitted to DAVID for functional annotation clustering by inserting the gene 
list and then choosing ??????????????????????????????unique gene identifier followed 
??????????????????????????????Homo sapiens??was selected as species to limit annotations. 
The uploaded gene list was analysed using, "Functional Annotation Clustering", selected 
from DAVID's functional annotation tools. Class stringency was set to medium, and options 
were defaulted to display Benjamini analysis. Selections of clusters were queried using the 
following terms: cell surface; regulation of cell death; regulation of cell proliferation; 
apoptosis and cell cycle process as onset progression of prostate cancer. Enrichment scores of 
1.3 or more was selected. A list of genes was created and further refined by removal of 
duplication resulting in the same genes generated from GO thus confirming results. 
2.5.1.4. Gene expression profiling using GeneHub-GEPIS 
The number of genes resulting following GO and DAVID analysis were then inserted into 
GeneHub-GEPIS database to eliminate genes already experimentally linked to prostate 
cancer through their expression within prostate cancer as annotated by this database, thus 
ensuring that genes selected as potential biomarkers would be novel. This database was 
specifically used due to the gene expression profiling of a large panel of normal and cancer 
tissues based on human EST sequence abundance. Either expressed or non-expressed genes 
in prostate cancer would be included within the new gene list generated. The following 
criteria were used: target species: Human; Search by Accession/Gene Symbol: e.g. ITGB1.  
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Bar graphs (figures 2.3 and 2.4) showing tumour (yellow bar) versus normal (blue bar) 
expression of various tissues for each gene was generated.  
2.5.1.5. Gene expression analysis using TiGER 
The same genes inserted in GeneHub-GEPIS were used in the TIGER database. Bar graphs 
(figures 2.5 and 2.6) showing results (red bar) of Expressed Sequence Tag (EST) Profile 
enrichment scores, with high enrichment being overly expressed in that specific tissue.  The 
gene view allowed information to be retrieved through a simple search engine by entering the 
gene symbol.  
ESTs may be used to identify gene transcripts, and are instrumental in gene discovery and in 
gene-sequence determination (Adams et al., 1991). A gene is considered as tissue-specific 
gene if it satisfies the two criteria: the enrichment score is greater than 5 and the P-value is 
smaller than 10-3.5. 
2.5.2. Literature mining of the Candidate genes 
The databases used for literature mining were: PubMed and Google Scholar. Genes were 
????????????????????????????????????????????????????????????????????????????????????????????
??????????????? ???????????? ??????????????? ?????????????? ????????????????????????????????
AND <gene name> was entered. All relevant literature, abstracts and journal articles were 
searched for information linking the genes as biomarkers for prostate cancer. All genes within 
the list generated that had been previously studied as candidate cancer or benign disease 
serum biomarkers in prostate cancer were eliminated and a final candidate gene list was 
generated. 
2.6. Results and Discussion 
2.6.1. Identifying possible candidate biomarkers 
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For the purpose of this study 21 genes known to be regulated by several miRNAs as 
identified in a ??????????????? ?Identification of miRNA's as specific biomarkers in prostate 
cancer diagnostics: ?????????????????????????????????????????????(Khan, PhD thesis, 2015) 
were the main focus. As data mining can only uncover patterns present in the data, the target 
data set must be large enough to contain these patterns while remaining concise enough to be 
mined. 13 miRNAs were identified as potential prostate cancer miRNA targets and a 
gene/protein list of 21 miRNA targeted genes were generated and linked to prostate cancer 
(Khan, 2015). 
The STRING database was used for prediction of protein-protein networks. The 21 genes 
were used individually as driver genes and a total of 300 additional genes/proteins were 
identified and extracted from the STRING database.. Through expansion of the initial 21 
miRNA targeted genes, intermediary proteins functioning in concert with these genes are 
identified through protein-protein interactions. Identification and characterization of protein?
protein interactions (PPIs) is one of the key aims in biological research.  More accurate PPI 
detection will also improve the ability to extract experimental data related to PPIs and 
provide evidence for each interaction (Niu et al., 2010).  
An example of an interaction network produced for TMX1 using STRING is shown in figure 
2.2.  
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Figure 2.2: TMX1 showing interactions of its 10 predicted functional partners using 
STRING. Different line colours between the proteins indicate the various types of interaction 
evidence for generating a specific interaction (Szklarczyk et al., 2015). 
Table 2.2: Number of genes extracted from STRING database for each miRNA targeted 
gene: 
miRNA Target Confidence Score Identified 
genes/interactions 
MiR1 ADNP 0.400 10 
MiR1 PAK7 0.700 20 
MiR1 RAB27A 0.700 20 
MiR1 ACVR1C 0.700 20 
MiR2 BTG2 0.400 10 
MiR3 SH3RF1 0.400 10 
MiR3 BFAR 0.400 10 
MiR4 PRKCI 0.700 20 
MiR4 PTPRC 0.700 20 
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MiR5 ING4 0.400 10 
MiR6 ATM 0.700 20 
MiR7 CLN8 0.400 10 
MiR8 CFLAR 0.700 20 
MiR8 CSRNP3 0.400 10 
MiR 9 YWHAZ 0.700 20 
MiR 9 TNFSF13B 0.700 20 
MiR 10 TMX1 0.400 10 
MiR 11 TNFSF15 0.400 10 
MiR 12 LIG4 0.400 10 
MiR 13 FOXC1 0.400 10 
MiR 13 MNT 0.400 10 
 
The gene list was refined and duplicates were eliminated using a Perl script, resulting in a 
total of 231 genes from the STRING database. 
GO analysis 
The identification of cell surface markers is critical to the development of new diagnostic and 
therapeutic modalities for the management of prostate cancer.  To identify potential markers 
for the diagnosis and treatment of prostate cancer, membrane-bound tumour antigens were 
searched for in that they may provide insights into the biology of prostate cancer progression 
(Reiter et al., 1998). Since these markers can be shed into the surrounding fluid and thus 
easily detected in various bodily fluids. 
The database GO was searched using the 231 genes identified and included the cellular 
component (CC) as part of the analysis GO terms generated a number of mapped 
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identifications of 26 genes in relation to their expression on the cell surface with a P ?value 
of <0.05.    
The smaller the p-value, the larger the significance since it indicates that the hypothesis under 
consideration may not adequately explain the observation. A small p-?????????????????????????
strong evidence as the p-value is widely used in statistical hypothesis testing (Nuzzo, 2014). 
Cellular component included terms such ??? ??????????? ??? ?????????????? ??????????? ??????
????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????et al., 2000). The GO concept is intended to make possible, in a 
flexible and dynamic way, the annotation of homologous gene and protein sequences in 
multiple organisms using a common vocabulary that results in the ability to query and 
retrieve genes and proteins based on their shared biology (Ashburner et al., 2000). 
Results obtained from GO is displayed in table 2.3 below. Column 1 indicates the annotation 
data category.  Column 2 indicates the number of reference genes linked to the annotation i.e. 
all genes within the database linked to this term. Column 3 shows the number of uploaded 
genes mapped to the annotation i.e. the number of genes within the list of 231 genes 
corresponding to this GO term. Column 4 shows the expected value, which is the number of 
genes expected in the list for this category, based on the reference list. Column 5 shows the 
Fold Enrichment of the genes observed in the uploaded list over the expected (number in the 
list divided by the expected number). The number is greater than 1, indicating that the 
category is overrepresented for this subset of genes in this study. Column 6 has either a + or - 
sign. The plus sign indicates over-representation of GO category. Column 7 has the p-value. 
A small p-value indicates that the number observed is significant and potentially interesting. 
A cut-off of 0.05 is recommended as a starting point (Thomas et al., 2016). Results obtained 
from GO and DAVID is shown in table 2.4 and displays the comparison thereof. 
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Table 2.3: Genes related to the GO term cellular component extracted from GO database 
 
Functional annotation using DAVID 
Two comparisons were performed,  DAVID  was mined for the exact same genes extracted 
from GO to confirm the GO term cellular component would result in the same output using 
DAVID.   
Genes extracted from DAVID database resulted in 20 clusters generated that was queried 
using the GO terms: 
Cluster 1 cell surface - enrichment score 6.25; cluster 4 regulation of cell death - enrichment 
score 4.19;   cluster 6 regulation of cell proliferation - enrichment score 3.2; cluster 11 
apoptosis - enrichment score 2.11 and cluster 18 cell cycle process - enrichment score 0.86. 
Combined clusters list and removal of duplication resulted in 26 genes. The confirmed 26 
genes from GO and DAVID analysis were then used to be further analysed for their 
expression in prostate cancer.   
 
 
GO cellular component 
complete 
Reference 
List 
Input  
List 
expected Fold Enrichment +/- P value 
external side of plasma 
membrane -  
cell surface 
779 26 8.46 3.07 + 6.27E-04 
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Table 2.4: Genes extracted from GO and DAVID  
 
2.6.2. Expression analysis 
TiGER and GeneHub-GEPIS are databases containing tissue specific enriched genes and 
expression analysis and these were used to  eliminate genes already experimentally linked to 
prostate cancer. All 26 genes were then mined in GeneHub-GEPIS, TIGER, PubMed and 
Google Scholar.  
Summary of expression analysis:  
GeneHub   TIGER  
8 non-expressed genes 5 non-expressed genes 
3 genes no EST hits 3 genes not found in 
databases 
 
Gene Ontology DAVID Name of gene 
CD22 CD22 hypothetical protein FLJ22814
CD3E CD3E CD3e molecule, epsilon (CD3-TCR complex)
CD4 CD4 CD4 molecule
EGFR EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)
ERP44 ERP44 Gene Name: TXNDC4 thioredoxin domain containing 4 (endoplasmic reticulum)
FAS FAS Fas (TNF receptor superfamily, member 6)
FASLG FASLG Fas ligand (TNF superfamily, member 6)
GP1BA GP1BA glycoprotein Ib (platelet), alpha polypeptide
IFNG IFNG interferon, gamma
IL13 IL13 interleukin 13
IL6 IL6 interleukin 6 (interferon, beta 2)
ITGA4 ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)
ITGAM ITGAM integrin, alpha M (complement component 3 receptor 3 subunit)
ITGB1 ITGB1 integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
LAMP1 LAMP1 lysosomal-associated membrane protein 1
LGALS1 LGALS1 lectin, galactoside-binding, soluble, 1 (galectin 1)
MMP7 MMP7 matrix metallopeptidase 7 (matrilysin, uterine
SEPT2 SEPT2 septin 2
SERPINE2 SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2, 
SHH SHH sonic hedgehog homolog (Drosophila
TDGF1 TDGF1 teratocarcinoma-derived growth factor 1
TNFRSF10A TNFRSF10A tumor necrosis factor receptor superfamily, member 10a
TNFRSF10B TNFRSF10B tumor necrosis factor receptor superfamily, member 10b
TNFRSF13C TNFRSF13C tumor necrosis factor receptor superfamily, member 13C
TNFRSF1A TNFRSF1A tumor necrosis factor receptor superfamily, member 1A
TNFSF4 TNFSF4 tumor necrosis factor (ligand) superfamily, member 4 (tax-transcriptionally activated glycoprotein 1, 34kDa)
Cell Surface  - 26 genes  
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In GeneHub-GEPIS, 8 genes showed no expression distribution in prostate tissue and 3 genes 
had no EST hits in the database. Outputs of 5 genes were non-expressed in the prostate in the 
TIGER database and results for 3 genes were not found in this database. Of the non-
expressed genes in these two databases, only 3 were common to both and only 1 gene, were 
not found in either database.  
 
 
Figure 2.3: Gene TNFSF4 showing no expression in both normal and tumour tissue as seen 
in the GeneHub-GEPIS database. 
 
Figure 2.4: Gene ITGB1 showing expression in both normal and tumour tissue, but more 
expression in tumour of the prostate in GeneHub-GEPIS database. 
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Figure 2.5: Gene TNFSF4 displaying no expression in prostate tissue in the TIGER database. 
 
Figure 2.6: Gene LAMP1 displaying expression in various tissues in TIGER database. 
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Literature mining was then used, in order to obtain genes of greater relevance to be validated 
as novel biomarkers for prostate cancer. 
2.6.3. Literature mining of the Candidate genes 
Of the 26 genes, only 6 showed no related articles to prostate cancer in PubMed and in 
Google Scholar of that 6, only 5 were not linked to prostate cancer. The resulting 6 genes 
from PubMed were chosen. Since Google Scholar offers results of inconsistent accuracy 
(Falagas, 2008).  
The final candidate gene list was narrowed down to the following 6 genes:  ERP44 (Gene 
Name: TXNDC4 thioredoxin domain containing 4 (endoplasmic reticulum), GP1BA 
(glycoprotein Ib (platelet), alpha polypeptide), IFNG (interferon, gamma), SEPT2 (septin 2), 
TNFRSF13C (tumour necrosis factor receptor superfamily, member 13C) and TNFSF4 
(tumour necrosis factor (ligand) superfamily, member 4 (tax-transcriptionally activated 
glycoprotein 1, 34 kDa).   
2.7. Discussion and Conclusion 
In this chapter the focus was on the diagnostic application of biomarkers using a 
bioinformatics approach. Using bioinformatics, the aim was to identify biomarkers for 
diagnosis of prostate cancer with a high sensitivity, specificity and accuracy. The biomarker 
should preferably be tissue specific, such that a change in serum level can be directly 
attributed to disease (for example, cancer) of that tissue (Diamandis, 2010).  Currently the 
most widely used serological biomarker include  prostate-specific antigen (PSA, also known 
as kallikrein-related peptidase (KLK) 3) in prostate cancer (Bostwick, 1994). This biomarker 
have been proven to be ineffective for the accurate diagnosis of prostate cancer hence the 
need to identify additional biomarkers for this disease which was the aim of this study 
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STRING database was used to look at known and predicted protein-protein associations 
(direct or indirect) for prostate cancer of the 21-miRNA target genes previously identified. 
The protein-protein interactions identified were based on experimental data, databases and 
literature and from predictions of genomic content analysis. The basic interaction unit in 
STRING is the functional association, i.e. a specific and productive functional relationship 
between two proteins, likely contributing to a common biological purpose  (Szklarczyk et al., 
2015). From STRING analysis 231 genes were generated which was further refined using 
GO, DAVID and expression analysis through TIGER and GeneHub-GEPIS. Gene Ontology 
(GO) analysis showed 26 out of the 231 genes being expressed on the cell surface with 
functional analysis using DAVID, showing the same number of genes to be linked to 
processes such as apoptosis, cell cycle and cancer onset and progression. 
A PubMed search revealed that 20 of the 26 genes identified had been previously studied in 
relation to prostate cancer. As seen in figure 2.3 and figure 2.5 the gene TNFSF4 were not 
expressed in prostate tissue in either TiGER or GeneHub-GEPIS database and is thus one of 
the six candidate genes identified. The coverage of the genes in TiGER and GeneHub-GEPIS 
databases with no association to prostate cancer was linked to and confirmed in literature 
mining to prostate cancer. 
These computational approaches led to six identified genes; ERP44, GP1BA, IFNG, SEPT2, 
TNFRSF13C and TNFSF4, as possible diagnostic biomarkers for prostate cancer. These 
results are promising, since the targeted biomarkers would be easily detectable in bodily 
fluids as the GO analysis of these genes are enriched for cell surface.  The identification of 
biomarkers for clinical applications remains an important issue for improving diagnostics, 
prognostics and therapy in many diseases, including prostate cancer. Investigation of these 
candidates should be prioritized for further verification and validation studies. The genes 
identified using an in silico approach within this chapter will be associated to transcription 
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factors and disease causing pathways in Chapter 3 to identify the underlying regulation of 
these genes and prognostic and predictive validation of these genes in prostate cancer 
(Chapter 4). 
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Chapter 3 
Identification of Transcription factors and disease associated pathways of the identified 
biomarkers 
3.1. Introduction 
Promoters assist in controlling gene expression, since it is at this site that the RNA 
polymerase binds for initiation of transcription. Multiple functional sites are involved in the 
binding of the polymerase and elements such as the TATA box, GC box, and CAAT box 
serve as binding sites for transcription factors (TFs). The proteins that mediate transcriptional 
regulation are called TFs. TFs play a central role in gene regulation but are not solely 
responsible. TFs influence the transcription of specific genes, essentially determining whether 
a particular gene will be turned "on" or "off" in an organism.  Each TF can regulate multiple 
genes (Phillips and Hoopes, 2008). 
Transcriptional activation of a gene requires the binding of specific transcription factors to 
regulatory DNA elements and the assembly of the preinitiation complex with RNA 
polymerase and RNA synthesis initiation. Many human oncogenes encode for transcription 
factors and some of the most prominent tumour suppressors (e.g. p53) are TFs.  TF families 
further increase the level of genetic complexity in eukaryotes and many TFs within the same 
family often work together to affect transcription of a single gene (Delgado and León, 2006). 
The identification of TF targets in prostate cancer provides potential new targets for 
therapeutic intervention of prostate cancer such as treatment strategies, disease progression 
and metastases. In this chapter TFs were identified and characterized with respect to their 
expression in the prostate.   Overexpression of TFs in prostate cancer implicates the 
development of carcinomas and the molecular diagnosis and treatment of prostate cancer.  In 
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order to facilitate the discovery of potential biomarkers, candidate genes, were investigated 
using TF annotation to identify linkage to prostate cancer.  
3.2. GeneCards 
GeneCards (www.genecards.org) is a readily available Web resource database that integrates 
data for 152 704 human genes from 125 sources (Fishilevich et al., 2016). GeneCards is 
accessible for searchable human gene annotations. Data are automatically mined from ?120 
sources and presented as an integrated web card for every human gene (Fishilevich et al., 
2016).  
It contains comprehensive information about human genes, including data about the cellular 
functions of their products, their involvement in diseases   and genomic, transcriptomic, 
proteomic, genetic, clinical and functional information. The presented information aims at 
giving immediate insight into current knowledge about the respective gene, including a focus 
on its functions in health and disease (Rebhan et al., 1998). 
3.3. KEGG Pathway database 
The KEGG (Kyoto Encyclopedia of Genes and Genomes)   (http://www.genome.jp/kegg/) 
database provides a systematic analysis of gene functions, linking genomic information with 
higher order functional information in terms of the network of interacting molecules 
(Kanehisa and Goto, 2000). 
KEGG is an integrated database resource consisting of seventeen main databases and  KEGG 
pathway database (http://www.genome.jp/kegg/pathway.html) is one of the main databases 
and is part of the research projects of the Kanehisa Laboratories used for pathway-based 
information (Kanehisa et al., 2010). KEGG PATHWAY contains scientific literatures on the 
biological molecular interaction and reaction networks, including protein-protein interaction, 
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protein-DNA binding, protein-ligand interaction and enzyme-mediated biomass reactions. 
Interactions within one specific biological process or function are drawn manually to pathway 
maps. Currently, there are 365 pathway maps collected from 113,760 references (Kanehisa et 
al., 2010). 
3.4. Aims 
1. Extract transcription factors associated to the six candidate genes   
2. Functionally annotate the identified TFs and their relation to prostate cancer  using 
GeneCards  
3. Identify the TFs that are linked to pathways associated in prostate cancer using the 
KEGG database 
 
3.5. Materials and methods 
 
Figure 3.1: Flow chart of the methodology used for identification of transcription factors of 
the candidate genes 
 
 
The 6 candidate genes selected as potential novel biomarkers 
are evaluated by GeneCards database to identify TFs 
associated to these genes
Identification of TFs that target the promoter regions of the 
candidate genes involved in prostate cancer. 
Identification of Pathways in KEGG linked to the TFs that 
target the promoter regions of the candidate genes involved 
in prostate cancer. 
 
 
 
 
80  
  
3.5.1. Identification of TFs using GeneCards 
The GeneCards database was launched at  www.genecards.org and used to extract the TFs that 
are associated to the six genes of interest. These six identified genes; ERP44, GP1BA, IFNG, 
??????????????????????????????????????????????????????????????????????????????box and 
selected for further exploration. The GeneCard showed all the data concerning the genes used 
as input. GeneCards sections and sub-headings include: Aliases, Disorders, Domains, Drugs, 
Expression, Function, Genomics, Localization, Orthologs, Paralogs, Pathways, Products, 
Proteins, Publications, Sources, Summaries, Transcripts and Variants of the gene of interest.   
The Genomics section displays the chromosome, cytogenetic band and map location of the 
GeneCards gene as extracted from GeneLoc, HGNC, Entrez Gene, Nature and miRBase, as 
well as genomic views from UCSC and Ensembl, RefSeq DNA sequence links and TF 
binding sites from Qiagen. The section, under the sub-???????? ???????????? ????????? ????
???????????????????TFs of the candidate genes are stored. The TF binding sites by Qiagen in 
the gene promoter displayed all related regulatory elements data, thus providing insight into 
the transcriptional regulation of the gene and cell proliferation, differentiation and 
tumourigenesis.  
3.5.2. Pathway discovery of the TFs associated to prostate cancer linked to the candidate 
genes using KEGG Pathway analysis 
Pathways in KEGG linked to the TFs that target the promoter regions of the candidate genes 
involved in prostate cancer were investigated and related to known prostate cancer pathways. 
Within the KEGG database, the KEGG Pathway database presented with pathway maps to 
molecular interaction and reaction networks of the prostate cancer pathway (See figure 3.2). 
The pathway map for prostate cancer was found under the sub-???????? ?Cancers: Specific 
??????? ??? ?????????????????????????? ??? ???? ???????? ??? ??????????? ??? ???????? ????????ed to 
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prostate cancer from GeneCards, these TFs (Table 3.2) were used in the KEGG Pathway as 
keyword entries.    
3.6. Results and Discussion 
Table 3.1: All TFs associated with the candidate genes identified in Chapter 2 extracted from 
GeneCards.  
GENE Regulatory Transcription factor 
ERP44 NF-kappaB1, NF-kappaB, C/EBPalpha, HTF, HFH-1,  
HNF-4alpha2, POU3F1 
GP1BA AP-1,c-Jun, ATF-2, NF-kappaB1, E2F, E2F-1, E2F-2, E2F-3a, E2F-
4 
IFNG STAT3, deltaCREB, CREB, POU2F1c, POU2F1b, POU2F1a, 
POU2F1, Ik-1, ATF-2, Hlf 
SEPT2 Max1, Nkx3-1v4, c-Myc, Nkx3-1, Nkx3-1v1, Nkx3-1v2, Nkx3-1v3, 
Cdc5 
TNFRSF13C AP-1, c-Jun, ATF-2, Sp1, p53, E47, USF-1, USF1, SEF-1(1) 
TNFSF4 AP-1, c-Jun, ATF-2, POU3F2, C/EBPalpha, POU6F1(c2), aMEF-2, 
MEF-2, MEF-2A, AML1a 
The common TFs are highlighted amongst this subset of genes and those associated with a 
particular gene. 
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3.6.1. Transcription factors that target the promoter regions of the candidate genes that 
are involved in or showing a direct link to prostate cancer 
NF-kappaB 
Nuclear factor-??????-?????????TF family that consists of five members in mammalian cells: 
NF-?????????????-?????????????????????????????????-Rel. NF-?????????????????????????????
physiological and pathological processes, including cell proliferation and differentiation, 
inflammatory and immune response, cell survival and apoptosis, cellular stress reactions and 
tumourigenesis (Yu et al., 2009; Beinke and Ley 2004). 
NF-???? ??? ????????? ??? ?? ?????????? ????????? ??-???? ?????? ?????? ??? ?????????? ??? ????
proteasome to produce the mature transcription factor NF-????????  As a cleaved product of 
p105, p50 only has a DNA binding domain and must form a heterodimer with RelA, RelB or 
C-Rel to act as a transcription factor to regulate its target gene transcription (Yu et al., 2009). 
Overexpression of p50 has been demonstrated in a large percentage of non-small cell 
carcinomas (Bours et al., 1994; Mukhopadhyay et al., 1995). p50 involvement leads to the 
development of inflammation-associated cancers, including hepatoma, some breast cancers 
and colitis-associated cancers (Yu et al., 2009). Wang et al., 2006 reported that a peptide 
designed to bind with p50 can inhibit NF-????????????????????????????????????????????????? 
There are reports demonstrating that TNF-?  (Tumour necrosis factor alpha) also induce cell 
anti-apoptosis associated with NF-?????????????? ???????????? ??????? ?????   (Sumitomo, 1999).  
The combination of TNF-alpha and NF-kappaB inhibitors could be constituted an effective 
therapy to TNF-alpha-resistant human prostate cancer cells  (Sumitomo, 1999). 
Transcription factor NF-kappaB1,   showing expression in various cancers was annotated to 
regulate genes ERP44 and GP1BA (as seen in table 3.1). 
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C/EBPalpha. 
The CCAAT/enhancer binding protein (C/EBP) family of TFs control the differentiation of a 
range of cell types, having key roles in regulating cellular proliferation through interaction 
with cell cycle proteins. C/EBPs have been described as both tumour promoters and tumour 
suppressors (Nerlov, 2007).   Common to gene ERP44 and gene TNFSF4,   ??????? ???
distinctive in that in addition to its transcriptional activity, it inhibits cell proliferation by 
several non-genomic mechanisms, causing it to be a tumour suppressor. In a study by Zhang 
et al., 2008, they found that ???????????????????????????????????????????????????????????????
highly expressed in prostate tumours. A significant observation is the frequent co-expression 
??? ??????? ????? ????????? ???????? (AR) in prostate cancer, particularly in the more 
aggressive metastatic tumours, which are both major regulators of transcription. This strongly 
suggests a combined role for them in determining the molecular phenotype of prostate 
tumours (Zhang et al., 2008).    
??????? ?????? ?? ????? ??? ???????????? ???? ??????????? ?????????? ????? ?????? ??????? ????
transcription of hepatic-specific and adipose-specific genes respectively.   In normal prostate, 
??????? ??? ?????????? ??? ???? ?????? ?????? ??? ???? ???????????? ??????????????? ??? ???????
inhibited epigenetically PSA expression and was accompanied by the loss of expression of 
AR (Yin et al., 2006).    
POU3F1 
POU domain class 3, transcription factor I  Oct-6 (Pou3f1, SCIP, Tst-1) is a member of the 
Pit-Oct-Unc (POU) family of transcription factors (Hofmann et al., 2010). 
In another study, candidate   genes identified showed a differential methylation pattern 
between normal and prostate cancer cell lines (LNCaP, PC3, DU145) and observed additional 
expression differences in a gene family belonging to transcription factors (STAT1, POU3F1, 
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MYOD) (Mishra et al., 2007).  New insight into Oct-6 gene regulation was uncovered, with a 
potential impact on the control of nerve myelination (Hofmann et al., 2010). POU3F1 was 
linked to gene ERP44 (table 3.1). 
AP-1 
Common to gene GP1BA, TNFRSF13C and TNFSF4, AP-1 nuclear transcriptional factors 
regulate expression of multiple genes involved in tumour growth, metastasis and 
angiogenesis. Activation of AP-1 has been implicated in prostate cancer development and 
growth, and therefore may represent promising therapeutic targets for cancer prevention and 
treatment (Uzzo et al., 2006). 
AP-1 is a heterodimer composed of proteins belonging to the c-Fos, c-Jun, ATF and JDP 
families.  AP-1 controls a number of cellular processes including differentiation, proliferation, 
and apoptosis (Ameyar et al., 2003).   In addition to being activated by oncogenic signal 
transduction cascades, AP-1 is itself strongly oncogenic (Ozanne et al., 2007). 
c-Jun 
In human prostate cancer, up-regulation of c-Jun proteins occurs in advanced disease and 
high levels of c-Jun expression are associated with disease recurrence.    In a study by Ouyang 
et al., 2008, the study revealed that an unappreciated role for AP-1 transcription factors in 
prostate cancer progression and identified c-Jun as a marker of high-risk prostate cancer 
(Ouyang et al., 2008). Associated to genes GP1BA, TNFRSF13C and TNFSF4, c-Jun TF 
shows expression in prostate cancer. 
E2F family  
The E2F family of TFs was found to be associated to only gene GP1BA of the candidate 
genes. The E2F family are involved in the cell cycle regulation and synthesis of DNA.  E2F1, 
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E2F2 and E2F3 function to promote the expression of cell cycle regulated genes and promote 
cell cycle progression, even if this promotion by deregulation of these E2F activities leads to 
defective cell cycling and apoptosis (DeGregori and Johnson, 2006).  E2F-1, a regulator of 
cell proliferation and viability, reportedly plays a role in the development of hormone-
refractory prostate cancer.   Its ability to repress AR transcription, elevated levels of E2F-1 
may contribute to the progression of hormone-refractory prostate cancer (Davis et al., 2006). 
STAT3 
Signal transducers and activators of transcription, STAT   as TFs are critical in mediating 
virtually all cytokine driven signaling.   Activation of one STAT family member, Stat3, 
associated to gene IFNG, in human prostate cancer cell lines and primary prostate tumours 
revealed that elevated Stat3 activity was localized primarily in the tumour cells of prostate 
carcinoma specimens (Mora et al., 2002). Stat3 expression occurs frequently in primary 
prostate adenocarcinomas and is critical for the growth and survival of prostate cancer cells. 
These studies further suggest that Stat3 signaling represents a potentially novel molecular 
target for prostate cancer therapy (Mora et al., 2002). The inhibition of Stat3 signaling blocks 
the growth of prostate cancer cells  and this suggest that targeting Stat3 signaling may yield a 
potential therapeutic intervention for prostate cancer (Ni et al., 2000).  
CREB 
Akt is an antiapoptotic serine-threonine kinase that regulates a number of critical cellular 
pathways including those leading to cellular proliferation and inhibition of apoptosis. One of 
the downstream targets of Akt is CREB and has been shown to phosphorylate CREB; it is 
possible that Akt-mediated activation of CREB plays an important role in prostate 
carcinogenesis (Garcia et al., 2006). The transcription factor CREB regulates genes involved 
in various cellular processes by binding to cAMP response element (CRE) sequences present 
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in their promoter regions (Kim et al., 2005).   Defects in apoptotic signaling pathways are 
often associated with uncontrolled cell proliferation, high mutation rate and malignant 
transformation. Transcription factors, such as the mammalian ATF/CREB family of 
transcriptional regulators, have diverse functions in controlling cell proliferation and 
apoptosis   (Persengiev and Green, 2003).    AIbZIP is a novel member of the CREB/ATF 
family of transcription factors that is highly expressed in prostate tumours and of which the 
expression is up-regulated by androgen in LNCaP cells (Qi et al., 2002). 
POU2F1 
POU2F1 (also known as Oct-1) is the transcription factor associated to gene IFNG and 
Obinata et al., 2012 demonstrated that Oct1 can be a prognostic factor in prostate cancer  and 
as a coregulator of AR and may lead to the development of a new therapeutic intervention for 
prostate cancer.  Oct1 is involved in the proliferation of LNCaP cells (Obinata et al., 2012). 
NKX3-1 
NKX3-1 is a prostatic tumour suppressor gene. It is an androgen-regulated, prostate-specific 
gene whose expression is predominantly localized to prostate epithelium. It acts as a 
transcription factor that has critical function in prostate development and tumour suppression.  
Based on this, NKX3.1 is a candidate gene for playing a role in the opposing processes of 
androgen-driven differentiation of prostatic tissue and loss of that differentiation during the 
progression of prostate cancer and early stages of prostate carcinogenesis.  Loss of NKX3A 
protein expression is a common finding in human prostate carcinomas and prostatic 
intraepithelial neoplasia (He et al., 1997).  Nkx3.1 is expressed early in the development of 
the prostate gland and is likely to play an important role in the differentiation of prostatic 
epithelia. Four splice variants (NKX3.1v1-4) (Korkmaz et al., 2000)  are associated with gene 
SEPT2.  
 
 
 
 
87  
  
Sp1 
Associated with gene TNFRSF13C, Sp1 is elevated in several malignancies including 
prostate cancer and is associated with the prognosis of patients of this disease (Sankpal et al., 
2011).   Studies have shown that in prostate cancer, Sp1 regulates important genes like 
androgen receptor, TGF-??? ?-Met, fatty acid synthase, matrix metalloprotein (MT1-MMP), 
????? ???? ?-integrin.  These results highlight the importance of Sp1 in prostate cancer and 
emphasize the potential therapeutic value of targeting Sp1 (Sankpal et al., 2011). 
p53 
Annotation of this TF was shown to gene TNFRSF13C, p53 mutations are detected in at least 
20% of advanced prostate carcinomas  and the overall p53 mutation rate is lower in prostate 
cancers than in many other cancers such as colon, lung, brain, breast, and bladder where p53 
is mutated in over 50% of the cases studied (Surget et al., 2014).  The p53 tumour suppressor 
protein is widely known for its role as a transcription factor that regulates the expression of 
stress response genes and mediates a variety of anti-proliferative processes. It is the most 
commonly mutated tumour suppressor in human cancers (Surget et al., 2014).  Reported by 
Isaacs et al., 1991, p53 gene mutations in prostate cancer cells suggested a functional role for 
the p53 gene in suppressing prostatic tumourigenesis. 
E47 
Transcription factor 3 (E2A immunoglobulin enhancer-binding factors E12/E47), also known 
as TCF3   is a multifunctional basic helix loop helix (bHLH), transcription factor, regulating 
transcription of target genes by homo- or heterodimerization with cell specific bHLH 
proteins. In general, E2A promotes cell differentiation, acts as a negative regulator of cell 
proliferation in normal cells and cancer cell lines. E2A, considered as a tumour suppressor is 
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highly expressed in prostate cancer. Loss of E2A promotes doxorubicin dependent apoptosis 
in prostate cancer cells (Patela and Chaudhary, 2012). 
c-Myc  
c-Myc affects the transcription of genes which participate in apoptosis. It is a key molecular 
integrator of cell cycle machinery and cellular metabolism and  determines the common and 
divergent patterns of c-Myc target gene expression in a variety of physiological and 
neoplastic conditions (Dang, 1999).  The transcriptionally active Max/Myc dimer promotes 
cell proliferation as well as apoptosis.  The protein Max is a member of the basic helix-loop-
helix leucine zipper (bHLHZ) family of transcription factors. It is able to form homodimers 
and heterodimers with other family members, which include Mad, Mxl1 and Myc. Myc is an 
oncoprotein implicated in cell proliferation, differentiation and apoptosis (Amati and Land, 
1994). 
Mutations of genes of the Myc family have been shown to be among the most frequently 
affected in the majority of human malignancies (Nair and Burley, 2006). Max1 and c-Myc 
are two TFs found to regulate the candidate gene IFNG only, of which Max1 showed no 
expression in prostate cancer from results obtained but numerous studies of human prostate 
cancer have demonstrated increased   c-Myc expression in the prostate as well as increased 
Myc gene copy number in up to 30% of tumours, even at the preneoplastic stage called 
prostate intraepithelial neoplasia (PIN) (Ellwood-Yen et al., 2003).   Two commonly used 
prostate tumour cell lines, LNCaP and PC-3, have significant c-Myc amplification and 
overexpression  (Zhong et al., 2000). 
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Table 3.2: Summary of TFs that target the promoter regions of the candidate genes involved 
in prostate cancer. 
GENE Prostate cancer associated Transcription factors 
ERP44 NF-kappaB1, NF-kappaB, C/EBPalpha, POU3F1 
GP1BA AP-1,c-Jun, NF-kappaB1, E2F, E2F-1, E2F-2, E2F-3a, E2F-4 
IFNG STAT3, deltaCREB, CREB, POU2F1c, POU2F1b, POU2F1a, 
POU2F1 
SEPT2 Nkx3-1v4, c-Myc, Nkx3-1, Nkx3-1v1, Nkx3-1v2, Nkx3-1v3,  
TNFRSF13C AP-1, c-Jun, Sp1, p53, E47 
TNFSF4 AP-1, c-Jun, C/EBPalpha,  
 
3.6.2. Transcription factors that target the promoter regions of the candidate genes that 
have shown no direct link to prostate cancer 
The following transcription factors; HTF, HFH-1, HNF-4alpha2,  ATF-2,   Ik-1, HLF,  Max1, 
POU3F2, POU6F1 (c2),  Cdc5, USF-1, USF1, SEF-1(1),  and aMEF-2, MEF-2, MEF-2A and 
AML1a showed no direct link to prostate cancer.  
HTF 
A TF, linked only to gene ERP44, HTF   (HER2 transcription factor)  from human epidermal 
growth factor receptor 2 has been identified as an AP-2 (activator protein-2) transcription 
factor.  Vernimmen et al., 2003 showed in their study that HTF is identical to AP-2 (activator 
protein-2).   Overexpression of HTF has been shown to play an important role in the 
development and progression of certain aggressive types of breast cancer. In recent years the 
protein has become an important biomarker and target of therapy for approximately 30% of 
breast cancer patients (Mitri et al., 2012).  
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HFH-1 
Hepatocyte nuclear factor-3 homologue 1 (HFH-1) belongs to the family of the FOX 
transcription factors (previously called HNF-3/forkhead transcription factors) that  play a role 
in tissue-specific and development gene regulation (Clevidence et al., 1993). 
HFH-1, linked only to gene ERP44 play important roles in early embryonic development and 
during development of many organ systems and represses the transcription of smooth muscle-
specific genes (Hoggatt et al., 2000). 
HNF-4alpha2 
Transcription factors, such as nuclear receptors activate transcription through interaction with 
coactivators.   Nuclear receptors comprise a large superfamily of relatively conserved 
transcription modulators that play a role in nearly every aspect of growth, differentiation, and 
development   (Erdmann et al., 2007).   Hepatocyte nuclear factor 4alpha (HNF4alpha) is a 
tissue-specific transcription factor expressed in many cell types, including pancreatic beta-
cells.   HNF4alpha2 is a spliced form of HNF4alpha   (Erdmann et al., 2007). This TF was 
associated to gene ERP44. 
ATF-2 
Common to genes GP1BA, IFNG, TNFRSF13C and TNFSF4,   ATF2 responds to stress-
related stimuli and may thereby influence cell proliferation, inflammation, apoptosis, 
oncogenesis, neurological development and function, and skeletal remodelling. A study, 
implicated abnormal activation of ATF-2 in growth and progression of mammalian skin 
tumours (Leslie and Bar-Eli, 2005). 
Heparan sulfate proteoglycans (HSPGs) are cell surface molecules that are extremely 
important in both development and cancer progression due to their regulation of cellular 
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processes such as angiogenesis, tumour growth, proliferation, tumour invasion and 
metastasis.  HS2ST1 (heparan sulfate 2-O-sulfotransferase, 2OST) is essential for maximal 
proliferation and invasion   of prostate cancer cells. HS2ST1 is upregulated by ATF2 
(Ferguson and Datta, 2011). 
POU family 
POU homologs are divided into six major classes, including common names: 
POU1 - POU1F1 (Pit-1); POU2 - POU2F1 (Oct-1), POU2F2 (Oct-2), POU2F3 (Oct-11); 
POU3 - POU3F1 (Oct-6; SCIP), POU3F2 (Oct-7; Brn-2), POU3F3 (Oct-8; Brn-1), POU3F4       
(Oct-9; Brn-4; DFN3); POU4 - POU4F1 (Brn-3a; RDC-1; Oct-T1), POU4F2 (Brn-3b; Brn-
3.2), POU4F3 (Brn-3c; Brn-3.1; DFNA15); POU5 - POU5F1(Oct-3; Oct-4), POU5F2 
(SPRM-1), Pou2/V; POU6 - POU6f1 (Brn-5; mPOU), POU6f2 (Emb; RPF-1) (Gold et al., 
2014). 
The transcription factors, POU3F2 and POU6F1 (c2), were linked to gene TNFSF4 which 
showed no expression in prostate cancer. In glioblastoma (GBM), a subset of stem-like 
tumour-propagating cells (TPCs) appears to drive tumour progression and underlie 
therapeutic resistance. A core set of neurodevelopmental TFs (POU3F2, SOX2, SALL2, and 
OLIG2)  co-ordinately bind and activate TPC-specific regulatory elements and are essential 
for GBM propagation (Suvà1 et al., 2014). 
POU6F1 (c2), referred to as brain-5 (Brn-5), is widely expressed with highest levels in the 
developing brain and spinal cord from embryonic day 12.5. In the adult, Brn-5 mRNA is 
most abundant in the brain, where it is diffusely expressed with the exception of enrichment 
in layer IV of the neocortex (Andersen et al., 1993). 
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Ik-1 
Linked to gene IFNG,  the Ikaros family are zinc finger transcription factors. They participate 
in a complex network of interactions with gene regulatory elements, other family members 
and other transcriptional regulators to control gene expression. Ikaros family members 
regulate important cell-fate decisions during haematopoiesis. Mutation of several family 
members results in haematological malignancies, especially those of a lymphoid nature (John 
and Ward, 2011).  
HLF 
HLF is a member of the PAR (proline and acidic amino acid-rich region) subfamily of b/ZIP 
(basic region leucine zipper) transcription factors  in acute lymphoblastic leukaemia (Hunger 
et al., 1992). Hepatic leukaemia factor inhibits cell death and is a candidate circadian factor 
(Watersa et al., 2013). Linked only to gene IFNG, this TF did not show any direct link to 
prostate cancer.  
CDC5 
The cell division cycle 5 (CDC5) is considered a putative transcription factor, as it is a MYB 
(a transcription factor)-related protein. In human and yeast, CDC5 has been shown to act as a 
component of the spliceosome to participate in mRNA splicing (Zhang et al., 2013). 
Polo-like kinases play critical roles during multiple stages of cell cycle progression. Polo-like 
kinase 1 (Plk1), a well-characterized member of serine/threonine kinases Plk family, has been 
shown to play pivotal roles in mitosis and cytokinesis in eukaryotic cells and plays critical 
roles in DNA replication and Pten null prostate cancer initiation.   Cdc5 is a Plk homolog 
known to play important roles in cell cycle regulation (Luo and Liu, 2012), also only linked 
to gene SEPT2. 
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USF-1 
USF is a family of transcription factors characterized by a highly conserved basic-helix-loop-
helix-leucine zipper (bHLH-zip) DNA-binding domain.  Upstream stimulatory factor 1(USF-
1, USF1), can activate transcription through pyrimidine-rich initiator (Inr) elements and E-
box motifs. This gene has been linked to familial combined hyperlipidaemia (FCHL) (Lee et 
al., 2006). This TF was associated to gene TNFRSF13C. 
SEF-1(1), aMEF-2, MEF-2, MEF-2A and AML1a 
aMEF-2, MEF-2   myocyte enhancer factor-2 (Mef2) proteins are a family of transcription 
factors which through control of gene expression are important regulators of cellular 
differentiation and consequently play a critical role in embryonic development  (Potthoff and 
Olson, 2007).  Studies have revealed a central role for the myocyte enhancer factor-2 (MEF2) 
family of transcription factors in linking calcium-dependent signaling pathways to the genes 
responsible for cell division, differentiation and death (McKinsey et al., 2002). The AML1 is 
associated with myelogenous leukaemias and encodes a DNA-binding protein. From AML1 
gene, two representative forms of proteins, AML1a and AML1b, are produced by alternative 
splicing (Tanaka et al., 1997). SEF-1(1), TF   showing no expression in prostate cancer, 
associated with gene TNFRSF13C. TFs (aMEF-2, MEF-2, MEF-2A and AML1a)  showed no 
expression in prostate cancer and were linked to gene TNFSF4, as seen in table 3.1. 
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3.6.3. KEGG Pathway Analysis 
 
Figure 3.2: Extracted from the KEGG Pathway database showing gene and TF links in 
Prostate Cancer (Kanehisa Laboratories©).  NKX3.1, PTEN, and p27 (shown in red) regulate 
the growth and survival of prostate cells in the normal prostate. Inadequate levels of PTEN 
and NKX3.1 lead to a reduction in p27 levels and to increased proliferation and decreased 
apoptosis (Kanehisa Laboratories©).  
Searching the KEGG pathway database with the TFs shown in table 3.2, associated to the six 
genes, resulted in  various TFs with some links to cancer however only 4 (NKX3.1, p53,  E2F 
and  CREB), showed association to the Prostate Cancer pathway.  
NKX3-1 TF is seen in the Prostate Cancer pathway and related to the gene of interest SEPT2 
as seen in table 3.2. p53 activation is induced by a number of stress signals, including DNA 
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damage, oxidative stress and was also found in the Prostate Cancer pathway linked to 
candidate gene TNFRSF13C. E2F, one of the TFs seen in the Prostate Cancer pathway was 
also found in Pathways in Cancer, p53 Signaling pathway and a number of other cancer 
pathways. E2F was linked to the gene of interest GP1BA. Another TF in the Prostate Cancer 
pathway, CREB (linked to gene of interest, IFNG) is also seen in other KEGG pathways such 
as the TNF Signaling pathway and Pathways in Cancer.  
The KEGG pathway database also revealed various TFs with links to cancer pathways. The 
TF AP-1 showed linkage to pathways such as TNF signaling pathway and Apoptosis pathway 
(Appendix B) and Cell Survival pathway as well as Inflammation and Immunity pathways.  
c-Jun, was found to be linked to the  Apoptosis pathway, TNF Signaling pathway, Pathways 
in Cancer (Appendix C) and  Colorectal Cancer pathway. The TFs, NF-kappaB involved in 
AGE-RAGE Signaling pathway and STAT3 TF is seen in  Pathways in Cancer. c-Myc is seen 
in the Transcriptional Misregulation in Cancer pathway and  Pathways in Cancer in the KEGG 
Pathway Database. Sp1 and E47 TFs were found in the Transcriptional Misregulation in 
Cancer pathway. The remaining TFs as seen in table 3.2 were not found within the KEGG 
Pathway databases revealing no results.   
3.7. Conclusion 
This chapter focused only on the TFs and the link of these TFs to pathways of the candidate 
biomarkers to prostate cancer. 
The set of 44 TFs found to be associated to the candidate genes; there are 15 TFs out of the 
44 that showed no experimental information about the genes they regulate with any direct 
links to prostate cancer.    
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The TFs that target the promoter region of the candidate genes have been reported to be 
involved in prostate cancer initiation, repression or progression. The remaining TFs linked to 
prostate cancer showing association to the candidate prostate cancer biomarkers (table 3.2); 
suggest that these genes could be potential diagnostic or prognostic markers as well as 
markers for monitoring therapeutic outcomes in prostate cancer. 
To assess the association of pathways and TFs provides new clues to genes, pathways, and 
TFs that contribute to the outcome of prostate cancer and might be exploited in designing 
new biomarkers thus demonstrating that effectively incorporating pathway information with 
TFs can provide better diagnostic evaluation.  
CREB, E2F, Nkx3-1 and p53 TFs were discovered to be linked to the genes IFNG, GP1BA, 
SEPT2 and TNFRSF13C respectively in prostate cancer and therefore shows that these genes 
can be assessed as possible biomarkers for prostate cancer. 
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Chapter 4 
Prognostic and Predictive validation of Genes using an in silico approach 
4.1. Introduction 
Genome-wide molecular profiles have served as sources for in silico discovery and/or 
validation of predictive/prognostic molecular biomarkers as well as therapeutic targets (Chen 
et al., 2014). Prognostic biomarkers are measurements made at diagnosis that provide 
???????????? ?????? ?? ?????????? ?????????? ??? ???? ???????? ??? ?reatment or in the presence of 
standard treatment. Predictive biomarkers are measured at baseline to identify patients who 
are likely or unlikely to benefit from a specific treatment (Simon, 2009). Prognostic markers 
help to stratify patients for treatment by identifying patients with different risks of outcome 
(e.g. recurrence of disease) and are important tools in the management of cancer and many 
other diseases (Riley et al., 2003). 
To obtain more accurate predictions, researchers have developed predictive tools (directed at 
predicting the probability of an outcome without considering the effect of time) and 
prognostic tools (directed at predicting the probability of an outcome over time) that are 
based on statistical models. Predictive and prognostic nomograms (devices that make 
predictions) have been introduced to predict the risk of the outcome of interest for the 
individual patient (Shariat et al., 2008).  
Several tools are available to conduct online survival analysis on genes of interest using 
publicly available data (Goswami and Nakshatri, 2014). 
For a molecular biomarker to be considered as a clinical test, the marker must demonstrate 
clinical magnitude of benefit, feasibility of clinical implementation and low costs. This 
incorporation of any clinical frameworks can be technically possible in various web-based 
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tools of genomic survival analysis by engaging disease domain experts in their development 
(Chen et al., 2014). 
Gene expression profiles are routinely applied to identify diagnostic and predictive 
biomarkers or novel targets for cancer and a few predictive markers identified in silico have 
also been validated for clinical, functional or mechanistic relevance in disease progression 
(Alinezhad et al., 2016). 
Several clinical features of prostate cancer including tumour stage, degree of tumour cell 
differentiation or Gleason score (GS) and the serum PSA are used in routine clinical practice 
to separate men into groups at low, intermediate, and high risk for tumour recurrence 
following local therapy (Singh et al., 2002). Majority of patients who undergo prostatectomy 
have low to intermediate risk clinical features and determining the prognosis for these 
patients remains difficult. Attempts to explore genetic correlates of tumour behaviour have 
found alterations in a number of candidate genes associated with prostate cancer progression 
and no single gene has been shown to have sufficient prognostic utility to warrant clinical 
implementation (Singh et al., 2002).  
To further examine the genes that were identified as possible novel biomarkers for prostate 
cancer by bioinformatics analysis, survival analysis methodologies have been adapted to the 
analysis of genomics data to link molecular information with clinical outcomes of interest 
especially prognosis. Genes recognized as being potential biomarkers for prostate cancer 
were evaluated to assess their relationship to prognosis of this disease. 
Validation studies provide conclusion about the expression of the candidate genes by using 
further bioinformatics tools. Uniting several databases enhances more accurate estimates of 
biomarkers for cancer diagnosis and prognosis. For the analysis of the candidate biomarkers 
 
 
 
 
107  
  
identified in Chapter 2, for prognostic value, several databases have been used to validate the 
six candidate genes in this study. 
4.2. SurvExpress® 
SurvExpress is a cancer-wide gene expression web-based database with clinical outcomes 
and a tool that provides survival analysis, risk assessment of cancer datasets and validations 
of survival biomarkers for cancer outcomes (Aguirre-Gamboa et al., 2013). It is a cancer 
database containing more than 20,000 samples and 130 datasets with censored clinical 
information covering tumours over 20 tissues. SurvExpress is the largest, most versatile, and 
quickest free tool available. SurvExpress can be accessed at 
http://bioinformatica.mty.itesm.mx/SurvExpress using a biomarker gene list as input 
(Aguirre-Gamboa et al., 2013). 
4.3. PROGgene 
PROGgene is a web accessible tool available at www.compbio.iupui.edu/proggene for 
researchers to identify potential prognostic biomarkers. It is useful in accelerating biomarker 
discovery in cancer and quickly providing results that may indicate disease-specific 
prognostic value of specific biomarkers. It has compiled data from public repositories such as 
Gene Expression Omnibus (GEO), European Bioinformatics Institute (EBI) Array Express 
and The Cancer Genome Atlas (Goswami and Nakshatri, 2013).  The database can be used to 
create prognostic (Kaplan-Meier, KM) plots for mRNAs and genes of interest using data in 
different cancers. A total of 64 datasets from 18 cancer types make this tool the most 
comprehensive prognostic biomarker identification tool to date and is primarily a hypothesis 
generation tool, which is meant to provide pursuable gene biomarkers in cancers of choice 
(Goswami and Nakshatri, 2013). 
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4.4. PrognoScan 
PrognoScan can be used for assessing the biological relationship between gene expression 
and prognosis. The database is publicly accessible at 
http://gibk21.bse.kyutech.ac.jp/PrognoScan/index.html. It is used to evaluate potential 
tumour markers and therapeutic targets and would accelerate cancer research. Cancer 
microarray datasets with clinical annotation were collected from the public domain including 
Gene Expression Omnibus (GEO) and individual laboratory web sites (Mizuno et al., 2009). 
The collection includes more than 40 datasets of various cancer types. The probe annotations 
were retrieved from GEO and ArrayExpress which was mapped to an Entrez Gene ID by 
querying the accompanied public identifier in UniGene database (Mizuno et al., 2009). 
PrognoScan employs the minimum p-value approach for grouping patients for survival 
analysis that finds the optimal cut-point in continuous gene expression measurements 
(Mizuno et al., 2009). Patients are divided into two (high and low) expression groups and the 
risk differences of the two groups are estimated by log-rank test. The optimal cut-point that 
gives the most pronounced pvalue (Pmin) is selected and conducts multiple correlated testing, 
p-value correction is conducted to control the error rate (Mizuno et al., 2009). 
4.5. Kaplan-Meier plots used as survival curves for prognostic value 
Kaplan-Meier plots using the Kaplan-Meier method were used to construct survival curves. 
The method, called the Kaplan-Meier estimator (also known as the product limit estimator), 
is based on a mathematical formula using information from those who have died and those 
who have survived to estimate the proportion of patients survived at any point during a study.  
The estimator is plotted over time. It computes the probabilities of occurrence of an event at a 
certain point in time. The resulting curve is called the Kaplan-Meier curve, which is a series 
of horizontal steps of declining magnitude that, when a large enough sample is taken, 
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approaches the true survival function for that population (Goel et al., 2010, Kaplan and 
Meier, 1958). The Kaplan-Meier approach estimates the survival curve in the presence of 
censored observations. Censoring means the total survival time for that subject cannot be 
accurately determined (Rich et al., 2010). 
Most survival analyses in cancer journals use some or all of Kaplan-Meier (KM) plots, log 
rank tests, and Cox (proportional hazards) regression (Clark et al., 2003). The main outcome 
under assessment is the time to an event of interest being the survival time, the time from 
complete remission to relapse or progression as equally as to the time from diagnosis to 
death. 
In each of the 3 gene expression databases used, KM plots were used to construct survival 
curves for the candidate prostate cancer biomarkers identified by this study due to the fact 
that the Kaplan-Meier method takes into account censored data, giving an estimate of 
recovery rates, probability of death, measurement of multiple variables to determine 
correlation of events. 
4.6. Aim 
The aim of this chapter is to evaluate the six identified candidate genes from Chapter 2, as 
prognostic and/or predictive biomarkers using various bioinformatics databases.  
4.7. Materials and Methods 
4.7.1. SurvExpress for the validation of prognostic biomarkers 
The list consisting of the 6 identified potential prostate cancer biomarkers were submitted to 
SurvExpress (http://bioinformatica.mty.itesm.mx/SurvExpress) homepage for validation as 
possible prognostic markers. The six genes (ERP44, GP1BA, IFNG, SEPT2, TNFRSF13C, 
???????????????????????????????????????????????????????????????????????????????????????????
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tissue type.  The default settings were used for ?????????????????????????????????????????????
probe sets/records will be a??????????????????????????????????????????????????-Normalized)]. 
The genes were then analysed using four different datasets. For this study, there were eight 
Prostate datasets available and four datasets were selected with the most number of samples 
and relevant clinical data; (a) Taylor MSKCC with 140 samples and clinical data of 
recurrence, Gleason score and stage, (b) Sboner Rubin GSE16560 with 281 samples and 
clinical data of Gleason score, (c) Kollmeyer-Jenkins Prostate GSE10645-GPL5858 with 596 
samples and clinical data of Survival, Age, PSA, Stage, Grade (d) PRAD-TCGA with 497 
samples and clinical data of survival.   
Search criteria analysis was performed according to the parameters in table 4.1. The rest of 
the parameters were left as default. The results generated, after the specification 
of parameters, showed Kaplan-Meier curves, plots and tables. Results were looked at as a 
panel and individually to identify prognostic or predictive biomarkers in prostate cancer from 
the list of putative biomarkers identified.  
Table 4.1: Search criteria for the four datasets used in SurvExpress 
Dataset  Censored Stratification 
Taylor MSKCC Recurrence_months Death 
Sboner Rubin GSE16560 Survival_month Outcome 
Kollmeyer-Jenkins 
GSE10645-GPL5858 
Survival_after_RRP Prostate.cancer.specific.death 
PRAD-TCGA Survival_days No stratification 
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4.7.2. Prognostic value of the candidate biomarkers using PROGgene 
The six candidate ?????? ?????????? ??? ??????? ????? ???????? ??? ???? ??????? ??????? ??????
provided and cancer type selected was ????????????????????????????????????????????????????
?????????????????????????????????????????????? ???????????????? ???????????????????????????
value as bifurcating point allowed samples to be divided into High and Low gene expression 
?????????? ??????? ??? ????? ???? ???????????? ??????????? ?????????? ? Molecular Sampling of 
??????????????????????????????????????????????????????????????????? data for only two out of 
the six genes found: GP1BA and TNFSF4. Kaplan-Meier plots were created as the results 
output for both genes.   
4.7.3. Analysis of the biological relationship between gene expression and prognosis 
within the PrognoScan database. 
The multiple genes were entered in the gene identifier space provided and submitted. This 
?????????????????????????????????????????????????????????????????????????????????????????????
type, subtype, endpoint, cohort, contributor, array type; probe ID, number of patients, optimal 
cutpoint, p-value (Pmin and Pcor). A statistically significant value of Pcor is given in red 
font. Each dataset has a link to the public domain where the raw data is archived (Mizuno et 
al?????????????????????????????????????????????????????????????????????ort of the individual gene 
which indicated further annotations for the dataset. 
The following plots where used to describe the prognostic value of each gene found in the 
PrognoScan databases (See figures 4.6, 4.7 and 4.8) (i) Expression plot showing patients 
ordered by the expression values of the given gene; the X-axis represents the accumulative 
number of patients and the Y-axis represents the expression value. Straight lines (cyan) show 
the optimal cut points that dichotomize patients into high (red) and low (blue) expression 
groups. (ii) Expression histogram resulting in the distribution of the expression value is 
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presented where the X-axis represents the number of patients and the Y-axis represents the 
expression value on the same scale as the expression plot. The line of the optimal cutpoint is 
also shown (cyan). (iii) P-value plot for each potential cut point of expression measurement; 
the X-axis represents the accumulative number of patients on the same scale as the expression 
plot and the Y-axis represents raw P-values on a log scale. The cut point to minimize the P-
value is determined and indicated by the cyan line. The grey line indicates the 5% 
significance level and (iv) Kaplan-Meier plot displays survival curves for high (red) and low 
(blue) expression groups at the optimal cut point are plotted; the X-axis represents time and 
the Y-axis represents survival rate. 95% confidence intervals for each group are also 
indicated by dotted lines (Mizuno et al., 2009). 
4.8. Results and Discussion 
4.8.1. Analysis of the six biomarkers as a panel using SurvExpress 
SurvExpress, an online biomarker validation tool and database, was used to explore the 
patient survival outcome in relation to the expression of the candidate biomarkers for prostate 
cancer. 
(A)                                                                        (B) 
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(C)                                                                       (D) 
 
Figure 4.1: Kaplan-Meier curves and performance of the six candidate biomarker panel 
in four datasets by SurvExpress: (A) Survival by month on Sboner Rubin prostate cancer 
dataset (B) Survival after Radical retropubic prostatectomy (RRP) on Kollmeyer Jerkins 
prostate cancer dataset (C) Recurrence on Taylor prostate cancer dataset and (D) Survival by 
days on Prostate adenocarcinoma (PRAD) - June 2016 dataset (refer to sections 4.2, 4.3, 4.4 
and 4.5 for patient data comparison of graphs in each database). 
The Sboner Rubin (Fig. 4.1A), Kollmeyer-Jenkins (Fig. 4.1B) and PRAD (Fig.4.1D) datasets 
demonstrated association of the biomarkers with patient survival. Taylor dataset also 
indicates clear association with disease recurrence (Fig. 4.1C). Analysis on PRAD data sets 
indicates that the genes are significantly associated with Prostate adenocarcinoma survival 
(Fig. 4.1D). The results of Kaplan?Meier (KM) plots for the four authors are summarized in 
Figure 4.1. 
4.8.1.1. Dataset: Taylor MSKCC Prostate 
Resulting in one gene not found SEPT2 and the rest of the 5 genes as seen in the Kaplan-
Meier survival curve showed highly significant differences between low and high expression 
of this gene panel in the probability that prostate cancer patients display recurrence of 
disease.  
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4.8.1.2. Dataset: Sboner Rubin GSE16560 
Results for 4 genes out of the 6 were not found (ERP44, SEPT2, TNFRSF13C, and IFNG) 
using this tool. As a panel of genes in this dataset, 2 genes: TNFSF4 and GP1BA were found 
but showed only slight prognostic value to the end of the study where patients highly 
expressing these genes (red) show poor prognosis compared to patients with low expression 
of these biomarkers. Biomarkers when combined could significantly predict the prognostic 
outcome of prostate cancer based on the difference in outcome between the higher and the 
lower expression of these genes (as shown in figure 4.1). 
4.8.1.3. Dataset: Kollmeyer-Jenkins Prostate GSE10645-GPL5858 
Results showed 5 genes not found: ERP44, GP1BA, SEPT2, TNFRSF13C, and TNFSF4, 
with only 1 gene (IFNG) found in this dataset, showing that after radical retropubic 
prostatectomy patients survives resulting in no prognostic value of this gene.  
4.8.1.4. Dataset: PRAD - TCGA - Prostate adenocarcinoma  
Although all genes were found in this dataset, the expression of genes resulted in no 
differential expression in low and high risk patients, which estimated the probability of 
survival in days with censoring occurring at the start of the study, giving an indication that 
the genes present poor prognostic value for prostate cancer. 
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Table 4.2: Result of survival analysis showing the significant genes based on p-????????????
0.05) using SurvExpress 
 Summary Result 
Biomarker ERP44, GP1BA, IFNG, SEPT2, TNFRSF13C, TNFSF4  
Database Prostate - PRAD - TCGA - Prostate adenocarcinoma June 2016  
Genes 6  
CI 0.694142  
Log.Rank 0.2469253  
Hazard.Ratio 2.191466  
C.I.Hazard.Ratio [0.561838339122112 - 8.54787633194716]  
pHR 0.2585771  
Correlation 0.006903972  
Significant.Genes 1  
Marginal.Genes 1  
Cox.Interesting GP1BA  
DEG 4  
DEG.Interesting GP1BA, IFNG, SEPT2, TNFSF4  
Notes Hazard Ratio was estimated by fitting a CoxPH using risk group as covariate. 
 
From the results seen, one gene out of the six on the dataset PRAD-TCGA Prostate 
adenocarcinoma showed promise as a good distinguishable prognostic markers based on the 
p-value (p < 0.05), GP1BA was significantly expressed with a p-value= 0.0350104. 
This result shows that in different datasets some genes are significant whereas that same 
genes are not significant in another dataset and this reason can be explained in a study that 
showed that the performance of biomarkers may differ in different populations, based on 
clinical information, probes per gene, the gene expression technology and the conditions used 
(Aguirre-Gamboa et al., 2013). 
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4.8.2. Analysis of the six biomarkers individually using SurvExpress 
As individual genes, the six candidate genes in SurvExpress generated little or no prognostic 
value, compared to the genes used as a panel; with certain genes showing no data within the 
dataset (see Figures 4.2, 4.3 and 4.4). 
4.8.2.1. Dataset: Taylor MSKCC Prostate 
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Figure 4.2: Kaplan-Meier curves and performance of the individual candidate 
biomarkers in dataset Taylor prostate cancer data by SurvExpress 
In this dataset, there is a good prognostic value for recurrence of disease in the beginning 
stages of the study for gene GP1BA based on the significant p-???????????????????????????????
statistically significant).  The rest of the genes found in this dataset, based on recurrence of 
disease, showed no prognostic value.  
4.8.2.2. Dataset: Sboner Rubin GSE16560 
                         GP1BA                  TNFSF4  
 
Figure 4.3: Kaplan-Meier curves and performance of the individual candidate 
biomarkers in dataset Sboner Rubin prostate cancer by SurvExpress 
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Displaying only the two genes found in this dataset, both genes again resulted in no 
significant prognostic value, to the end of the study in patients expressing these genes. 
4.8.2.3. Dataset: Kollmeyer-Jenkins Prostate GSE10645-GPL5858 
For gene, IFNG in this dataset (only 1 gene found) ? the output showed the same results as 
the panel of genes as seen in figure 4.1B.  
4.8.2.4. Dataset: PRAD - TCGA - Prostate adenocarcinoma  
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Figure 4.4: Kaplan-Meier curves and performance of the individual candidate 
biomarkers in dataset PRAD - TCGA - Prostate adenocarcinoma June 2016 by 
SurvExpress 
From the survival curves of this dataset (Figure 4.2), the 5 genes found did not show 
significant value in predicting the disease outcome in relation to prostate adenocarcinoma. 
4.8.3. Determining the prognostic value the of candidate biomarkers within the 
PROGgene database 
To further determine the prognostic value of the individual biomarker candidates in overall 
survival of prostate cancer, the PROGgene database was used. Using this software the 
outcome was individual gene results with no gene panels looked at for the six candidate 
genes. The same dataset GSE16560 as in SurvExpress was used in PROGgene, with only 
slight variations in the survival curves (comparison of figure 4.3) but the outcome being the 
same. During this study of dataset GSE16560, all patients with the expression of these genes, 
whether low or highly expressed, resulted in no prognostic value for prostate cancer.  
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Figure 4.5: Kaplan-Meier plot for genes GP1BA and TNFSF4 in GSE16560 dataset by 
PROGgene 
4.8.4. Expression analysis and prognostic value of candidate genes using PrognoScan 
The prognostic value of the six candidate biomarkers was also determined using the 
PrognoScan database and the results represented with expression plots, expression 
histograms, P-value plots and Kaplan-Meier plots (survival curves). Again, not all genes were 
found in this database, with the following three genes: SEPT2, GP1BA (see appendix D) and 
TNFSF4 (See appendix E) and only one gene, SEPT2 (figure 4.6), showed possible 
prognostic value. The probability of survival with this gene highly expressed is significant in 
the early stages of the disease, showing possibility as a good prognostic biomarker at that 
stage. There is differential expression between the low and high expression during this stage 
for SEPT2. See table 4.3 displaying a significant p-value for this gene.  
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Figure 4.6: Expression plot, Expression histogram, P-value plot and Kaplan-Meier plots 
for high and low SEPT2 -expressing groups in prostate cancer 
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Table 4.3: PrognoScan SEPT2 gene result-­‐Statistically significant gene with corrected p-
value= 0.026191 
DATA  POSTPROCESSING   None  
PROBE_NAME   DAP1_0256  [6K  DASL]  
PROBE_DESCRIPTION   septin  2  
GENE_SYMBOL   SEPT2  
GENE_DESCRIPTION   septin  2  
DATASET   GSE16560  
CANCER_TYPE   Prostate  cancer  
SUBTYPE       
N   281  
ENDPOINT   Overall  Survival  
PERIOD   Months  
COHORT   Sweden  (1977-­‐1999)  
ARRAY  TYPE   6K  DASL  
CONTRIBUTOR   Sboner  
SAMPLE  PREPARATION   DASL  
CUTPOINT   0.84  
MINIMUM  P-­‐VALUE   0.001033  
CORRECTED  P-­‐VALUE   0.026191  
ln(HRhigh  /  HRlow)   0.59  
COX  P-­‐VALUE   0.254584  
ln(HR)   0.22  
HR  [95%  CI]   1.25  [0.85  -­‐  1.83]  
 
4.9. Conclusion 
Despite the introduction of PSA screening, the mortality from prostate cancer has remained 
relatively high. Although the benefits of PSA screening are widely debated, this serum 
marker remains one of only a few preoperative parameters of prognostic utility (Henshall et 
al., 2003). In silico biomarker validation could be a substantially more cost-effective strategy 
for biomarker development, which typically requires costly and lengthy processes. Survival 
analysis tools and resources, clinically deployed genome-based biomarkers are still scarce, 
highlighting the unresolved challenges in biomarker development from genomic studies 
(Chen et al., 2014). 
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Novel and clinical markers for prostate cancer diagnosis, prognosis, and prediction is 
essential to the optimal identification and treatment of this disease and to bring potential 
biomarkers from the laboratory environment into clinical use at the patient bedside requires a 
comprehensive pursuit and rigorous analysis (Tricoli et al., 2004). 
The prognostic gene signatures related to patient outcome such as survival time and tumour 
stage must be genes that are important in tumour development and progression (Li et al., 
2015). 
Larger patient cohorts are needed for prostate cancer, as compared to other cancers such as 
breast cancer, for data outcomes not to be ambiguous (Sutcliffeet al., 2009). This was evident 
in the comparison of the PROGgene and SurvExpress results of GSE16560 dataset. A 
limitation is that the cohort was not big enough therefore the genes were difficult to assess for 
prognosis for prostate cancer patients in general.  
Although, the results of the SurvExpress analysis revealed gene expression differences that 
were not significantly sufficient to be distinguished as strong prognostic biomarkers, one 
marker, GP1BA did stand out, supporting its prognostic value based on the statistical p-value.   
Another gene, from the Prognoscan database SEPT2 shows promise in that has some 
prognostic value in the early stages of the disease. 
This study provides some promising evidence that bioinformatics data mining can be a highly 
beneficial means to identify novel biomarkers, although combined with clinical biomarker 
validation by qRT-PCR, using a molecular approach and functional evaluation of candidate 
genes, it can be considered for a detailed follow-up study on selected candidates in the near 
future. 
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Chapter 5 
General Discussion and Summary 
5.1 General discussion 
The measurement of serum PSA is currently the most useful biomarker to aid in earlier 
detection of prostate cancer and is performed on millions of men worldwide. Urgently needed 
in the study of disease is the development of biomarkers that can detect curable disease 
earlier and not detect advanced disease better (Petricoin et al., 2004). 
miRNAs are important regulators of biologic processes in prostate cancer progression and in 
recent years, much effort has been invested in improving patient care by substituting 
procedures such as DRE or prostate biopsy with miRNA analysis in patient serum or plasma. 
In prostate cancer, diagnosis and follow-up monitoring after therapies are some of the major 
challenges for its clinical management. Patients undergo repetitive biopsies, being invasive 
and not decisive, even if coupled with PSA and digital rectal examination (DRE) (Fabris et 
al., 2016). Although several markers have reasonable operating characteristics, no individual 
marker is ideal and therefore it is possible that a combination of biomarkers may provide 
better predictive value (Makarov et al., 2009).  
There are several molecular events that are believed to occur in a large percentage of prostate 
carcinomas such as down-regulation of the NKX3.1 homeobox gene represents a frequent 
and critical event in prostate cancer initiation and is likely to involve multiple mechanisms. 
Studies have suggested a role for MYC overexpression in prostate cancer initiation as nuclear 
MYC protein is up-regulated in many PIN lesions and the majority of carcinomas (Shen and 
Abate-Shen, 2010). PTEN was originally identified as a tumour suppressor that is frequently 
mutated or deleted in prostate cancer. miRNAs have specific roles in regulation of critical 
target genes, as the cluster miR-106b-25 negatively regulates PTEN expression. Suitable 
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combinations of markers may be successful in cumulatively predicting outcomes, as enabled 
by new technologies such as molecular systems pathology (Shen and Abate-Shen, 2010).  
Throughout prostate development and maturation, genes such as nkx3.1, FOXA1 and AR 
function to mediate gland formation and cellular differentiation. Activation of developmental 
genes within differentiated prostate epithelium can promote hyperplastic proliferation and/or 
progression of prostate cancer. Many of detected mutations still require validation to 
determine if there is any functional consequence and it represents the current paradigm shift 
from single molecule research to genome-wide analysis (Schrecengost and Knudsen, 2013). 
Despite extensive research efforts, very few biomarkers of prostate cancer have been 
successfully implemented into clinical practice today. Biomarkers for prostate cancer should 
be addressed to distinguish BPH from prostate cancer, to detect the aggressive forms from the 
indolent cases, and to identify metastatic cancer predictors (Tefekli and Tunc, 2013).  
5.2. Summary 
Chapter 2 
In chapter 2, the 13 miRNAs that were identified as potential prostate cancer miRNA targets 
and their 21 target genes were generated and shown to be related to prostate cancer (Khan, 
PhD thesis, 2015) were expanded on by identifying their co-expressed genes using the 
STRING database and a total of 300 additional genes/proteins were identified and extracted.  
The gene list was then refined and duplicates were eliminated, resulting in a total of 231 
genes from the STRING database   as possible potential biomarkers for early diagnosis of 
prostate cancer.  Cell surface gene products were identified using the GO database with the 
231 genes identified in STRING generating a number of mapped identifications of 26 genes 
in relation to their expression on the cell surface with a P ?value of <0.05. A confirmation of 
the generated gene list by functional annotation clustering in DAVID database  resulted in 20 
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clusters that were queried using the GO terms: cell surface, regulation of cell death, 
regulation of cell proliferation,  apoptosis and  cell cycle process and in turn also resulted in 
the same 26 genes as GO, which then was used in the TiGER and GeneHub-GEPIS databases 
known for tissue specific enriched genes and expression analysis. These databases were used 
to eliminate genes already experimentally linked to prostate cancer.  
Literature mining: PubMed and Google Scholar were used, in order to obtain genes of greater 
relevance to be validated as novel biomarkers for prostate cancer.  The final candidate gene 
list was narrowed down to the following 6 genes:   ERP44, GP1BA, IFNG, SEPT2, 
TNFRSF13C and TNFSF4 for prostate cancer and would be easily detectable in bodily fluids 
since the GO analysis of these genes is enriched for cell surface expression.  
Chapter 3  
The 6 genes identified in silico (Chapter 2) were associated with TFs and pathways in 
Chapter 3. The TFs were identified using GeneCards and were annotated to confirm 
regulatory control in cancer processes and specifically prostate cancer.  44 TFs were found to 
be associated to the candidate genes and 15 of these TFs showed no experimental information 
about the genes they regulate and any direct links to prostate cancer.   Identification of 
Pathways in the KEGG database were linked to the TFs that target the promoter regions of 
the candidate genes involved in prostate cancer and resulted in various TFs with some links 
to cancer however only 4 (NKX3.1, p53, E2F and CREB), showed association to the Prostate 
Cancer pathway. CREB, E2F, Nkx3-1 and p53 TFs were discovered to be linked to the genes 
IFNG, GP1BA, SEPT2 and TNFRSF13C respectively therefore showing that these genes can 
be assessed as potential biomarkers for prostate cancer. 
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Chapter 4  
In this chapter, the six identified candidate genes from Chapter 2 were evaluated as 
prognostic and/or predictive biomarkers using SurvExpress as a panel as well as individually.  
The genes were analysed using four different datasets.  One gene out of the six, GP1BA was 
significantly expressed, on the dataset PRAD-TCGA Prostate adenocarcinoma and showed 
promise as a good distinguishable prognostic marker based on the p-value (p < 0.05). As 
individual genes, the six candidate genes in SurvExpress generated little or no prognostic 
value, compared to the genes used as a panel; with certain genes showing no data within the 
dataset.    The prognostic value of the candidate biomarkers using PROGgene database  
allowed samples to be divided into High and Low gene expression groups resulted in no 
prognostic value for prostate cancer. Expression analysis and prognostic value of candidate 
genes using PrognoScan showed one gene, SEPT2 with differential expression significant at 
early stages of the disease being  possibility a good prognostic biomarker.  
5.3. Future Work for this study 
This study provides some promising evidence that bioinformatics data mining can be a highly 
beneficial means to identify novel biomarkers, although combined with clinical biomarker 
validation by qRT-PCR, using a molecular approach and functional evaluation of candidate 
genes, it can be considered for a detailed follow-up study on selected candidates in the near 
future to evaluate their roles in disease initiation and progression of prostate cancer using cell 
lines as well as patient samples. 
Large scale protein interactions and miRNA target prediction data were used in this study and 
future directions for this work could use additional protein interaction networks, different 
miRNA target prediction algorithms and different expression data sets to reveal more miRNA 
regulated genes in prostate cancer as diagnostic biomarkers.  
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The 6 genes of interest identified (Chapter 2) would require validation at a molecular level. 
Various types of assays can be used in the biomarker method validation process and range 
from the relatively low technology end such as immunohistochemistry (IHC) to 
immunoassays to the high technology end including platforms for genomics, proteomics and 
multiplex ligand-binding assays.   A genomics approach such as gene expression analysis 
microarrays has become the standard technology used for target identification and validation. 
Immunoassays are routinely used for protein biomarker assessments due to its 
straightforward clinical application and translation into a potential diagnostic assay. The 
analytical platforms used are based on nuclear magnetic resonance spectroscopy and the 
combination of liquid chromatography with mass spectroscopy.   Molecular and functional 
imaging technologies are used to assess cell proliferation and apoptosis, cellular metabolism, 
angiogenesis and vascular dynamics. The right choice of assay is an important first step to 
successful biomarker method validation (Chau et al., 2008). 
5.4. Future perspectives 
Future research should focus on validation of already existing biomarkers and the discovery 
of new markers to identify men with aggressive prostate cancer, PSA is not specific for 
prostate cancer and serum levels are elevated in common benign diseases (Makarov et al., 
2009).  
The future biomarker studies for prostate cancer should focus on biomarker candidates that 
address the current gaps in biomarker development, including prognostic and predictive 
biomarkers. One approach to identifying predictive biomarkers is to focus on genomic 
disease signatures, which influence the biological characteristics of an individual cancer 
(Prensner et al., 2012).  
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Challenges for future studies will be to integrate epidemiological studies with molecular 
investigations and clinical analyses to gain fundamental insights into how environmental, 
dietary, and lifestyle influences contribute to the development of prostate cancer, much work 
remains to be done to enhance the overall rate of prostate cancer survival.  
High‑throughput technology methods and advances in molecular biology are helping and 
accelerating the exploration to useful biomarkers. Future studies are needed to reconfirm the 
features of the existing biomarkers and further discover novel potential ones to better predict 
the presence of the disease (Qu et al., 2014). 
With the emergence of novel high throughput omics-based technologies, there is a need for 
better in silico computational and bioinformatics tools to improve clinical inferences drawn 
from huge databases (Adeola et al., 2016). The ideal biomarker should be economical, 
consistent, non-invasive, easily accessible, and quickly quantifiable. A drawback of the PSA 
test has resulted in a concerted effort to develop replacement-screening tools for prostate 
cancer. It will be a challenge to replace PSA entirely due to its minimally invasive nature and 
low cost but there is a pressing need to complement PSA with biomarkers that can increase 
the specificity and sensitivity of a screen. A panel of diagnostic and prognostic biomarkers 
that will work in conjunction with PSA will be ideal (Velonas et al., 2013).  
Also, prognostic markers are particularly important at the time of initial diagnosis of prostate 
cancer since it varies widely in patient outcome. No prognostic marker can accurately predict 
outcome for an individual patient, it provides a probability estimate of outcome for a 
heterogeneous population of patients. Prognostic markers may be crucial to reduce 
overtreatment of patients with indolent malignancy and so minimizing the side effects of 
adjuvant systemic therapies, and to avoid under treatment of patients with aggressive and life-
threatening malignancy, which would be recommended in receiving the most appropriate 
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local and systemic therapy.  Tumour biomarkers might be useful for risk assessment, 
screening for early cancer detection, diagnosis, prognosis, selection and monitoring of 
anticancer therapy (Mordente et al., 2015). 
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  APPENDICES 
Appendix A: Genes found within the Prostate cancer Pathway (Extracted from the KEGG 
Pathway database) 
CDKN1B; cyclin dependent kinase inhibitor 1B  
CDK2; cyclin dependent kinase 2  
CCNE1; cyclin E1  
CCNE2; cyclin E2  
RB1; RB transcriptional corepressor 1  
E2F1; E2F transcription factor 1  
E2F2; E2F transcription factor 2  
E2F3; E2F transcription factor 3  
INS; insulin  
PDGFA; platelet derived growth factor subunit A  
PDGFB; platelet derived growth factor subunit B  
PDGFC; platelet derived growth factor C  
PDGFD; platelet derived growth factor D  
EGF; epidermal growth factor  
TGFA; transforming growth factor alpha  
IGF1; insulin like growth factor 1  
INSRR; insulin receptor related receptor  
PDGFRA; platelet derived growth factor receptor alpha  
PDGFRB; platelet derived growth factor receptor beta  
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FGFR1; fibroblast growth factor receptor 1  
FGFR2; fibroblast growth factor receptor 2 
EGFR; epidermal growth factor receptor  
ERBB2; erb-b2 receptor tyrosine kinase 2 
IGF1R; insulin like growth factor 1 receptor  
PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit alpha  
PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit delta  
PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit beta  
PIK3CG; phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit gamma  
PIK3R1; phosphoinositide-3-kinase regulatory subunit 1  
PIK3R5; phosphoinositide-3-kinase regulatory subunit 5  
PIK3R2; phosphoinositide-3-kinase regulatory subunit 2  
PIK3R3; phosphoinositide-3-kinase regulatory subunit 3  
PTEN; phosphatase and tensin homolog  
PDPK1; 3-phosphoinositide dependent protein kinase 1  
NKX3-1; NK3 homeobox 1  
AKT1; AKT serine/threonine kinase 1 
AKT2; AKT serine/threonine kinase 2  
AKT3; AKT serine/threonine kinase 3  
CASP9; caspase 9  
BAD; BCL2 associated agonist of cell death  
FOXO1; forkhead box O1  
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CDKN1A; cyclin dependent kinase inhibitor 1A  
MDM2; MDM2 proto-oncogene  
TP53; tumor protein p53  
GSK3B; glycogen synthase kinase 3 beta  
CREB1; cAMP responsive element binding protein 1  
ATF4; activating transcription factor 4  
33 
 
 
CREB3; cAMP responsive element binding protein 3  
CREB3L1; cAMP responsive element binding protein 3 
like 1  
CREB3L2; cAMP responsive element binding protein 3 
like 2  
CREB3L3; cAMP responsive element binding protein 3 
like 3  
CREB3L4; cAMP responsive element binding protein 3 
like 4  
CREB5; cAMP responsive element binding protein 5  
CTNNB1; catenin beta 1  
CREBBP; CREB binding protein  
EP300; E1A binding protein p300  
TCF7; transcription factor 7 (T-cell specific, HMG-box)  
TCF7L1; transcription factor 7 like 1 
TCF7L2; transcription factor 7 like 2  
LEF1; lymphoid enhancer binding factor 1  
CCND1; cyclin D1 
CHUK; conserved helix-loop-helix ubiquitous kinase  
IKBKB; inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase beta  
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IKBKG; inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase gamma  
NFKBIA; NFKB inhibitor alpha  
NFKB1; nuclear factor kappa B subunit 1  
RELA; RELA proto-oncogene, NF-kB subunit  
BCL2; BCL2, apoptosis regulator  
MTOR; mechanistic target of rapamycin  
GRB2; growth factor receptor bound protein 2  
SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1  
SOS2; SOS Ras/Rho guanine nucleotide exchange factor 
2  
HRAS; HRas proto-oncogene, GTPase  
KRAS; KRAS proto-oncogene, GTPase 
NRAS; neuroblastoma RAS viral oncogene homolog  
ARAF; A-Raf proto-oncogene, serine/threonine kinase  
BRAF; B-Raf proto-oncogene, serine/threonine kinase  
RAF1; Raf-1 proto-oncogene, serine/threonine kinase  
MAP2K1; mitogen-activated protein kinase kinase 1  
MAP2K2; mitogen-activated protein kinase kinase 2  
MAPK1; mitogen-activated protein kinase 1 
MAPK3; mitogen-activated protein kinase 3  
SRD5A2; steroid 5 alpha-reductase 2  
AR; androgen receptor  
HSP90AA1; heat shock protein 90 alpha family class A 
member 1  
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HSP90AB1; heat shock protein 90 alpha family class B 
member 1  
HSP90B1; heat shock protein 90 beta family member 1  
KLK3; kallikrein related peptidase 3  
GSTP1; glutathione S-transferase pi 1  
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Appendix B:  Apoptosis Pathway (Extracted from the KEGG Pathway database) 
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Appendix C: Pathways in Cancer (Extracted from the KEGG Pathway database) 
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Appendix D: Expression plot, Expression histogram, P-value plot and Kaplan-Meier plots 
for high and low GP1BA-expressing groups in prostate cancer. Expression analysis and 
prognostic value of GP1BA gene using PrognoScan database 
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Appendix E: Expression plot, Expression histogram, P-value plot and Kaplan-Meier plots 
for high and low TNFSF4-expressing groups in prostate cancer. Expression analysis and 
prognostic value of TNFSF4 gene using PrognoScan database 
 
 
 
  
  
  
 
 
 
 
